biopharma strategy action annual report asdon left zhen jin research scientist kai pharmaceuticals south san francisco compares tissue samples part cardio vascular disease collaboration bristolmyers squibb lead compound collaboration novel investigational medica tion emergency room treatment acute heart attack compound phase iib clinical development granted fast track status us food drug administration potential treat lifethreatening disease address unmet medical need nextgeneration biopharma leader bristolmyers squibb committed helping patients prevail serious disease complementing enhancing internal capabilities suite innovative alliances partnerships acquisitions call string pearls strategy collaboration kai part strategy includes seven major transactions completed date since august front cover bristolmyers squibb scientist wallingford connecticut examines well plate screening drug candidates disease targets well contains onemillionth liter particular compound thats barely enough see yet plenty advanced highspeed robotic technol ogy use plate others screen million compounds time one tiny wells plate perhaps next breakthrough medication cancer hivaids cardiovas cular disease alzheimers serious illness part biopharma aboutbiopharma strategy action stockholders bristolmyers squibb emerged stronger leaner effective enterprise much better positioned continue delivering innovative medicines help patients prevail fight serious disease year global economic upheaval productivity transformation initiative continuing industry challenges threw many companies announced december expanded july track kept sights trained vision represents ongoing longterm companywide effort laid december reset cost base fundamentally changing way nextgeneration biopharma leader work quicker agile profitable executed transformative changes maximize near track achieve total billion term growth improving companys earnings annual productivity cost savings avoidance base beyond first wave initiatives announced december financial perspective alone targets billion cost savings avoidance punctuated wins led percent sales growth second wave announced july targeted billion year solid growth broad additional billion based geographically across products productivity efforts set motion cascade driven plavix abilify virology franchise well actions building momentum make us faster newer products orencia sprycel competitive touching areas business total net sales continuing operations culture strategy teams divisions worldwide billion compared billion embraced advanced selfsustaining improve net fully diluted earnings per share ments ensuring greater shareholder value coming continuing operations years long term cents weve recast global operating model better continue track project one suit vision focused biopharma company best nearterm growth rates industry resources reallocated prioritize percent compound annual growth rate nongaap valuable opportunities partnerships thirdparty earnings per share continuing operations manufacturers helping us maximize assets base without rebasing continuing rationalize mature brands portfolio convatec wound care business sold consolidate global supply network simplify august geographic footprint implement efficient gotomarket model better resource management general administrative functions closely tied sales earnings growth also simplifying standardizing cases improved gross margins reflect new approach sourcing processes services improving global expenses sourcing practices way manage cash flow shifting business portfolio strong cash balance puts us one heart biopharma excellent position oncology compounds preclinical strategy medicines give make investments innovation clinical development meaningful hope patients critical future programs discovery physicians bring value biopharma company five years ago shareholders customers areas alzheimers disease took decisive steps medicines serious disease hepatitis c unmet medical ensure robust future bio changes weve made need huge growing demon logic medicines specialty drugs business portfolio expenses mean strated proof confidence focus assets completely free focus invest two key compounds across weve captained massive cleanly medicines pharmaceuticals therapeutic areas delivered executed reallocation resources segment company accounted new compounds exploratory monetized nonpharma assets percent net sales development discovery become peripheral strategy making investing core proud expanded ben research development processes business part engaging new efits bringing patients efficient partnerships alliances deepen existing portfolio prepare expertise capabilities offerings likelihood generic branded nurturing strong partnerships certain select therapeutic areas competition plavix year expanding capabilities august completed extremely proud product partnerships sales medical imaging continues play critical role historic strength bristolmyers business convatec wound medical regimens cardiovascular squibb continues central care business gross proceeds disease patients worldwide biopharma philosophy billion abilify secondlargest product latestage products strategic also announced initial public remarkable growth rate partnerships large phar offering mead johnson nutrition percent reflecting value maceutical companies helping us completed early part developing additional indications balance risk reach patients retaining percent stake major depressive disorder freeing resources make room mead johnson poised con patients tell us make investment core tinue deriving steady source income feel like development commercialization growth vital infant research development capabilities currently engaged pediatric nutrition business efforts continue lead steady broad partnerships many time believe access pub flow milestones latestage key products including plavix avapro lic investment help mead johnson pipeline assets continued advance abilify atripla well several grow independent company submitted onglyza latestage medicines including nonpharma divestitures diabetes medicine develop onglyza dapagliflozin apixaban well sale percent stake ing jointly astrazeneca bolster early midstage imclone contributed total cash united states europe japan research pipeline forming balance approximately billion received approval erbitux select alliances biotech partners end ability complete sprycel january series transactions transactions amass also continue advance call string pearls liquidity time access cash earlystage pipeline fastgrow new pearls helping us bol increasingly fleeting speaks lead ing oncology pipeline example ster pipeline balance ership foresight making three significant cancer portfolio beyond bristolmyers squibb better company medicines marketplace building clusters expertise bristolmyers squibb annual reportkey therapeutic areas great unmet medical need including cardiovascular disease solid tumors bristolmyers squibb hematologic malignancies hepatitis emerged c alzheimers disease stronger leaner exciting work gained ground following path effective enterprise acquisition adnexus among years transactions acquisi tion kosan biosciences global collaborations exelixis pdl biopharma kai pharmaceuticals early added global collaboration agreement zymo genetics well collaboration james cornelius chairman chief executive officer agreement nissan chemical industries teijin pharma instance transactions management team importantly weve positioned weve made build string im pleased weve solidified selves strong partner biotech pearls required us learn act worldclass management team one circles gaining higher profile quickly decisively opportunities best ive encountered years demonstrating ability nurture emerge rapidly reprioritiz working health care industry innovation assets talent ing resources spot basis cross expanded management worth noting weve pursued functional swat teams prepared council include brian daniels string pearls rigor turn dime called upon leads global development also restraint bid research new disease areas evaluate medical affairs carlo de notariste imclone met counteroffer unfamiliar assets structure trans fani leads technical operations deemed expensive acted actions accordingly global support functions discipline withdrew offer smaller leaner scale also batrice cazala leads global decision ultimately resulted accelerating shift agile commercialization europe approximately billion proceeds cando culture instance set mc meets weekly focal shares sold earned us topdown tone accomplish point key operational issues respect investment community less eliminating cor discussion resolution porate aviation group relocating early made addi biopharma culture shift executive office space manhat tional changes management underpinning ultimate success tan modest accommodations team governance structure bet transition biopharma com time embrac ter align biopharma company pany cultural shift transforming ing several employeedriven initiatives established executive committee approach daily work speed decisionmaking clarify meet asneeded basis deal announced new lines accountability critical strategic issues strategy said needed holding accountability facing company joining come agile entrepreneurial central tenet culture sig committee lamberto andreotti accountable achieve goals naling importance maintaining elliott sigal jeanmarc huet year weve measured prog highest levels ethical conduct time lamberto ress areas rapid pace compliance also taking responsi also appointed president chief change accomplishments bility individual decisions operating officer elected pipeline disease areas biopharma leader future bristolmyers cancer squibb dedicated discovering developing innovative medicines address serious unmet atherosclerosisthrombosis medical needs key disease areas believe better help patients prevail diabetes compounds research programs discovery earliest stages research compounds exploratory development preclinical early obesity clinical development full development compounds investigational drugs laterstage clinical psychiatric disorders development submitted regulatory agencies approval finally medicines marketed alzheimers disease product development driving current future growth also undergoing continued clinical development determine whether additional indica hepatitis tions formulations benefit patients hivaids investigational compound research program represented chart bar discovery exploratory development immunology full development marketed product development including rheumatoid arthritis solid organ transplant rejection pipeline chart january member companys board directors heritage including active role global health jeanmarc promoted executive vice president care leader year observe decade since chief financial officer given responsibility company foundation first committed million oversee strategy productivity addition finance address epidemic hivaids africa time investment grew million biopharma leadership future largest public private pledge cause vastly improved enterprise look future december committed another million optimism confidence next years foundation continue good work weve done bring tough challenges industry global secure future africa philanthropic initia economy large know wellprepared tives elsewhere around world success uncertain age course greatest leadership opportunity result transformation become one inspires employees work harder every much admirable enterprise internal day ability connect millions patients external measures fifth annual survey barrons around world patients grateful worlds mostrespected companies bristol mission business extend enhance human life myers squibb included first time three years ranking th based variety attributes includ ing strong management sound business strategy ethical practices financial performance james cornelius also proud move biopharma chairman chief executive officer future retaining important aspects march bristolmyers squibb annual reportfinancial review managements discussion analysis financial condition results operations quantitative qualitative disclosures market risk consolidated financial statements notes consolidated financial statements reports management controls procedures reports independent registered public accounting firm fiveyear financial summary bristolmyers squibb managements discussion analysis financial condition results operations executive summary company bristolmyers squibb company may referred bristolmyers squibb bms company global biopharmaceutical nutritional products company whose mission extend enhance human life providing highest quality pharmaceutical nutritional products company engaged discovery development licensing manufacturing marketing distribution sale pharmaceuticals nutritional products company two reportable segmentspharmaceuticals nutritionals pharmaceuticals segment consists global pharmaceuticalbiotechnology international consumer medicines business accounted approximately companys net sales nutritionals segment consists mead johnson nutrition company mead johnson primarily infant formula childrens nutritionals business accounted approximately companys net sales financial highlights following table summary operating activity year ended december dollars millions net sales net earnings continuing operations net earnings discontinued operations net earnings net cashdebt net sales companys net sales continuing operations increased plavix clopidogrel bisulfate abilify aripiprazole continue drive worldwide sales growth sales increases respectively significant contributions sales growth also provided key products including orencia abatacept sprycel dasatinib hiv hepatitis portfolio net earnings continued operations increase net earnings continuing operations attributed increased sales growth favorability gross margins portion attributed favorable product mix well cost savings avoidances resulting companys productivity transformation initiative pti million aftertax gain related tendering companys shares imclone systems inc imclone also significant impact net earnings continuing operations amongst specified items discussed expensesgains net earnings discontinued operations company completed divestitures bristolmyers squibb medical imaging medical imaging business gross purchase price million resulting aftertax loss million well convatec business gross purchase price approximately billion resulting aftertax gain billion results medical imaging convatec businesses related gains losses included discontinued operations years presented net cashdebt net cashdebt position december improved due proceeds billion divestiture convatec medical imaging businesses proceeds billion sale imclone shares cash generated operating activities billion adequate fund dividend payments billion well capital expenditure payments million annual report business environment company conducts business primarily within pharmaceuticalbiotechnology industry highly competitive subject numerous government regulations many competitive factors may significantly affect companys sales products including product efficacy safety price costeffectiveness marketing effectiveness product labeling quality control quality assurance manufacturing operations research development new products successfully compete business health care industry company must demonstrate products offer medical benefits well cost advantages currently companys new product introductions compete products already market therapeutic category addition potential competition new products competitors may introduce future company manufactures branded products priced higher generic products generic competition one companys leading challenges globally pharmaceuticalbiotechnology industry majority innovative products commercial value usually realized period product market exclusivity product loses exclusivity longer protected patent subject new competing products form generic brands upon exclusivity loss company lose major portion products sales short period time currently generic versions biological products approved united states us law however law could change future even absence new legislation us food drug administration fda taking steps toward allowing generic versions certain biologics competitors seeking approval biological products must file safety efficacy data address challenges biologics manufacturing involves complex processes costly traditional pharmaceutical operations us internationally health care industry subject various governmentimposed regulations authorizing prices price controls continue impact companys sales us congress state legislatures considered number proposals enacted laws could result major changes current health care system either nationally state level driven part budget concerns medicaid access reimbursement restrictions implemented states proposed many others addition medicare prescription drug improvement modernization act provides outpatient prescription drug coverage senior citizens us legislation modest favorable impact company result increase number seniors drug coverage time continues potential negative impact us pharmaceutical business could result pricing pressures controls many markets outside us company operates environments governmentmandated costcontainment programs regulatory bodies groups exert downward pressure pricing pricing freedom limited united kingdom uk instance operation profit control plan germany operation reference price system companies also face significant delays market access new products two years elapse drug approval new medicines become available countries growth managed care organizations mcos us played large role competition surrounds health care industry mcos seek reduce health care expenditures participants making volume purchases entering longterm contracts negotiate discounts various pharmaceutical providers market potential created large pool participants marketing prescription drugs mcos become important part companys strategy companies compete inclusion mco formularies company generally successful major products included company believes developments managed care industry including continued consolidation continue generally downward pressure prices pharmaceuticalbiotechnology production processes complex highly regulated vary widely product product shifting adding manufacturing capacity lengthy process requiring significant capital expenditures regulatory approvals biologics manufacturing involves complex processes traditional pharmaceutical operations biologics become important companys product portfolio company continue make arrangements thirdparty manufacturers make substantial investments increase internal capacity produce biologics commercial scale one investment new state oftheart manufacturing facility production biologics devens massachusetts construction began may company maintained competitive position market strives uphold position dependent success discovering developing innovative costeffective products serve unmet medical need company expanded pti activities order achieve additional savings order reduce costs streamline operations rationalize global manufacturing become productive competitive biopharmaceutical company company subsidiaries subject number significant pending lawsuits claims proceedings investigations possible time reasonably assess final outcome investigations litigations additional discussion legal matters see note legal proceedings contingencies bristolmyers squibb strategy companys multiyear strategy transformation nextgeneration biopharma company strategy encompasses aspects geographies business yield substantial cost savings cost avoidance increase companys financial flexibility take advantage attractive market opportunities may arise managing costs one part companys overall strategy transitions nextgeneration biopharma company focused delivering present commitments maximizing nearterm growth opportunities improving earnings base company announced pti designed create total billion annual productivity savings cost avoidance first wave announced december targeted billion savings cost avoidance second wave announced july targeted additional billion savings cost avoidance company continue focus development biopharmaceutical business maintain growth investing research development new product pipeline company continue invest key growth products including specialty biologic medicines cardiovascular metabolic drugs company seeking reallocate resources continue string pearls strategy enable strategic transactions acquisition kosan biosciences inc kosan strategic alliances global codevelopment cocommercialization agreement exelixis inc exelixis global collaboration agreement zymogenetics inc zymogenetics entered company continue pursuing partnerships expanding collaborative arrangements biopharmaceutical companies continue entering strategic alliances third parties order obtain rights develop manufacture market andor sell pharmaceutical products rights owned third parties company continue maximize value noncore businesses company completed divestiture convatec medical imaging businesses company also sold mature brands business located egypt new product pipeline developments sprycel january company announced approval sprycel japan ixempra december company announced new data studies ixempra ixabepilone plus capecitabine compared capecitabine alone including prespecified sub set analysis demonstrating significant increase progression free survival patients triple negative breast cancer november committee medicinal products human use chmp europe issued negative opinion marketing authorization application ixempra treatment patients metastatic breast cancer company requested reexamination case currently consideration chmp exelixis december company announced global collaboration exelixis covering two novel molecules cancer associated development programs exelixis ' xl small molecule inhibitor met vegfr ret xl currently phase iii development medullary thyroid cancer exelixis ' xl small molecule inhibitor raf kinase currently phase development treatment patients advanced solid tumor malignancies agreement company receives development commercialization rights programs dapagliflozin december company astrazeneca plc astrazeneca announced expansion worldwide collaboration include development commercialization dapagliflozin japan dapagliflozin one two investigational drugs joint development companies currently studied phase iii clinical trials several countries including us assess efficacy safety oncedaily treatment type diabetes erbitux january company marketing partner imclone whollyowned subsidiary eli lilly company lilly announced companies withdraw eventually resubmit application fda broaden use erbitux cetuximab include firstline treatment patients advanced nonsmall cell lung cancer combination platinum based chemotherapy cisplatinvinorelbine october fda accepted filing priority review supplemental biologics license application sbla broaden indication erbitux include use combination platinumbased chemotherapy firstline treatment patients recurrent metastatic squamous cell carcinoma head neck annual report october publication study results showing metastatic colorectal cancer mcrc patients wildtype normal kras tumors treated erbitux plus best supportive care bsc statistically significant increase overall survival progressionfree survival compared treated bsc alone specifically patients whose tumors normal mutant negative kras gene achieved near twofold improvement overall survival progressionfree survival patients treated bsc alone patients mutated kras tumors significant difference overall progressionfree survival treated erbitux plus bsc treated bsc alone company fda discussions regarding possible label changes related study september announcement five year data showing significant improvements overall survival patients locally regionally advanced head neck cancer extreme study published new england journal medicine showing erbitux improved survival firstline recurrent andor metastatic head neck cancer july erbitux received marketing approval japan treatment patients advanced recurrent colorectal cancer may annual meeting american society clinical oncology asco landmark phase iii study flex showed addition erbitux platinumbased chemotherapy significantly increased overall survival firstline treatment patients advanced nonsmall cell lung cancer compared platinumbased chemotherapy alone abilify supplemental new drug application abilify approved fda february acute treatment manic mixed episodes associated certain pediatric patients age bipolar disorder fda approval received may new abilify indications pediatric bipolar ages maintenance therapy pediatric schizophrenia ages maintenance therapy addon treatment lithium valproate acute treatment bipolar disorder pediatric age adult patients european commission authorized marketing abilify march treatment moderate severe manic episodes bipolar disorder prevention new manic episode patients experienced predominantly manic episodes whose manic episodes responded abilify treatment orencia october company announced results month study showed orencia compared placebo pbo significantly improved multiple aspects healthrelated quality life physical psychosocial well pain sleep quality juvenile idiopathic arthritis jia patients ages years results part study looking safety efficacy orencia children jia failed previous treatments methotrexate mtx biologics october company announced results phase iiib study adult patients early moderatetosevere erosive rheumatoid arthritis ra never received previous mtx treatment study showed orencia combination mtx significantly patients achieve disease activity score using creactive proteindefined remission compared mtx plus pbo safety profile orencia combination mtx similar mtx plus pbo also quarter company filed sbla fda use orencia patients early ra june new phase ii data presented european league rheumatism demonstrated orencia may delay development ra people undifferentiated inflammatory arthritis april orencia approved fda treatment juvenile ra additionally us label orencia revised indication means orencia appropriate option patients moderatetosevere ra regardless prior treatment received baraclude company announced november data two separate cohort evaluations longterm treatment baraclude entecavir associated improved liver histology including improvement fibrosis chronic hepatitis b patients histology data presented th annual meeting american association study liver diseases new data march asian pacific association study liver meeting demonstrated continued low incidence resistance baraclude nucleosidenaive patients five years treatment important many chronic hepatitis b patients requiring longterm treatment bristolmyers squibb reyataz october company announced week data castle study patients reyatazr arm achieved undetectable viral load defined human immunodeficiency virus hiv rna less copiesml compared patients lopinavirr arm difference treatment arms may related discontinuation rate reyatazr arm discontinuation rate lopinavirr arm october fda approved use reyataz atazanavir sulfate milligram oncedaily boosted ritonavir milligram part combination therapy previously untreated treatmentnave hiv infected patients use daily reyatazritonavir hiv infected treatmentnave adult patients based upon week results castle study demonstrated similar antiviral efficacy reyatazritonavir twicedaily lopinavirritonavir part hiv combination therapy treatmentnave hiv infected adult patients data castle study published august issue lancet june european approval received expanded indication reyataz mg oncedaily boosted ritonavir mg part combination therapy treatmentnave hiv infected patients february first data comparing boosted reyataz reyataz plus ritonavir lopinavirritonavir presented congress retroviruses opportunistic infections apixaban september company development partner pfizer inc pfizer announced phase ii study appraise apixaban novel anticoagulant provided encouraging trends suggesting anticoagulation apixaban top current standards care continued beyond initial hospitalization may reduce risk second heart attack stroke death primary endpoint met phase iii study apixaban prevention venous thromboembolism vte patients undergoing total knee replacement results trial necessitate changes protocols ongoing apixaban studies companies considering studies preventing vte knee surgery submit us regulatory filing vte prevention second half previously communicated programs directed toward prevention vte including european medicines evaluation agency registration studies treatment vte acute coronary syndrome prevention stroke atrial fibrillation continue planned ipilimumab favorable updated survival data announced september three phase ii studies ipilimumab saxagliptin favorable results announced september phase iii studies onglyza saxagliptin regulatory submissions onglyza made us europe june july respectively annual scientific sessions american diabetes association phase iii study demonstrated saxagliptin produced significant reductions key measures glucose control treatmentnave people type diabetes compared placebo elotuzumab company entered agreement pdl biopharma inc august global development commercialization elotuzumab antics antibody currently phase development multiple myeloma kai may company entered agreement kai pharmaceuticals inc kai develop commercialize kais novel acute heart attack medicine kai kosan june bristolmyers squibb completed acquisition kosan biosciences inc kosan cancer therapeutics company library novel compounds including hsp inhibitors cancer microtubule stabilizers may additional potential neurodegenerative diseases zymogenetics january company zymogenetics announced global collaboration peginterferon lambda novel type interferon currently phase ib development treatment hepatitis c related development program plavix european committee medicinal products human use march issued positive opinion recommending approval milligram loading dose tablet plavix positive opinion ratified european commission annual report results operations following discussions companys results continuing operations exclude results related medical imaging business prior divestiture january convatec business prior divestiture august medical imaging convatec previously presented component former health care operating segment renamed convatec operating segment subsequent medical imaging divestiture businesses segregated continuing operations included discontinued operations periods presented companys results operations follows change dollars millions vs vs net sales earnings continuing operations income taxes minority interest net sales provision income taxes effective tax rate net earnings continuing operations net sales net sales composition changes net sales follows vs vs net sales analysis change analysis change total foreign total foreign dollars millions change volume price exchange change volume price exchange us nonus total increase us net sales primarily driven growth key us pharmaceutical products described detail increases international net sales aided weakened us dollar relative certain foreign currencies especially euro uk pound general companys business seasonal information us pharmaceutical prescriber demand reference made table within pharmaceuticals sets forth comparison changes net sales estimated total prescription growth retail mail order customers certain companys key pharmaceuticals products new products sold us pharmaceuticals business us nonus net sales based upon location customer bristolmyers squibb companys net sales segment follows net sales change total net sales dollars millions vs vs pharmaceuticals nutritionals total company recognizes revenue net various sales adjustments arrive net sales reported consolidated statements earnings adjustments referred grosstonet sales adjustments described critical accounting policies reconciliations companys gross sales net sales significant category grosstonet sales adjustments follows years ended december dollars millions gross sales grosstonet sales adjustments prime vendor chargebacks women infants children wic rebates managed health care rebates contract discounts medicaid rebates cash discounts sales returns adjustments total grosstonet sales adjustments net sales grosstonet adjustments primarily function gross sales activity typically correlated current sales trends case managed health care rebates contract discounts medicaid rebates cash discounts adjustments managed health care rebates contract discounts medicaid rebates also affected changes sales mix contractual legislative discount rates increases managed health care rebates contract discounts also impacted reduction reserves related tricare retail pharmacy refund program prime vendor chargebacks decreased throughout result lower sales taxol paclitaxel attributed loss exclusivity women infant children wic rebates decrease related net impact several wic contract transactions increase sales returns primarily attributed increased provisions pravachol pravastatin sodium driven higher retail sales returns previously assumed loss exclusivity zerit stavudine variance sales returns compared prior year attributed higher provisions cardiovascular nonexclusive brands discontinued commercialization tequin gatifloxacin annual report activities ending balances significant category grosstonet sales adjustments follows managed health women care rebates infants prime vendor children contract medicaid cash sales dollars millions chargebacks wic rebates discounts rebates discounts returns adjustments total balance january provision related sales made current period provision related sales made prior periods returns payments impact foreign currency translation discontinued operations balance december provision related sales made current period provision related sales made prior periods returns payments impact foreign currency translation discontinued operations balance december company recorded grosstonet sales adjustments related sales made prior periods significant items included charges sales returns million million primarily resulting higher expected returns certain nonexclusive products significant revisions made estimates grosstonet sales adjustments pharmaceuticals composition changes pharmaceutical net sales follows vs vs net sales analysis change analysis change total foreign total foreign dollars millions change volume price exchange change volume price exchange us nonus total key us pharmaceutical products contributed growth sales plavix abilify represented approximately total us pharmaceuticals net sales represented approximately total growth pharmaceuticals sales compared prior year plavix abilify represented approximately total us pharmaceuticals net sales contributed approximately total growth us pharmaceuticals net sales growth offsets decreases us net sales attributed generic competition pravachol international pharmaceuticals sales aided weakened us dollar many foreign currencies compared previous period companys reported international net sales include copromotion sales reported alliance partner sanofiaventis sanofi plavix avaproavalide irbesartanirbesartanhydrochlorothiazide continued show growth bristolmyers squibb net sales key pharmaceutical products represent total pharmaceutical net sales respectively following table details us international pharmaceuticals net sales key products percentage change prior year well foreign exchange impact compared prior year commentary detailing reasons significant variances key product provided change attributable foreign net sales change exchange dollars millions vs vs vs vs cardiovascular plavix us nonus total avaproavalide us nonus total pravachol us nonus total virology reyataz us nonus total sustiva franchise total revenue us nonus total baraclude us nonus na total na oncology erbitux us nonus total taxol us nonus total sprycel us nonus na total na ixempra us na nonus total na affective psychiatric disorders abilify us nonus total immunoscience orencia us nonus na na total negative pravachol us sales reflect higher retail sales returns previously assumed change excess annual report plavix platelet aggregation inhibitor part companys alliance sanofi us sales increases primarily attributed increased prescription demand higher average selling prices demand negatively affected beginning third quarter second quarter launch generic clopidogrel bisulfate generic distribution channel substantially depleted june estimated total us prescription demand clopidogrel bisulfate branded generic increased approximately respectively whereas estimated us prescription demand branded plavix increased respectively international net sales negatively impacted august launch clopidogrel alternative salt clopidogrel besylate launched germany see note legal proceedings contingenciesplavix litigation discussion plavix exclusivity litigation us eu avaproavalide known eu aprovelkarvea angiotensin ii receptor blocker treatment hypertension diabetic nephropathy also part sanofi alliance worldwide sales increases primarily attributed higher average selling prices offset declines overall demand total us prescription demand avaproavalide decreased approximately approximately pravachol hmg coa reductase inhibitor treatment hypercholesterolemia reducing risk heart attack worldwide sales decreases attributed continued generic competition us key european markets market exclusivity ended us april eu countries us sales negatively impacted higher retail sales returns previously assumed reyataz protease inhibitor treatment hiv us sales increases primarily due higher prescription demand respectively international sales increase primarily due higher demand across markets europe key driver due june approval frontline treatment growth international revenue attributed increased demand europe latin america sustiva franchise nonnucleoside reverse transcriptase inhibitor treatment hiv includes sustiva efavirenz antiretroviral drug bulk efavirenz also included combination therapy atripla efavirenez mg emtricitabine mgtenofovir disoproxil fumarate mg product sold joint venture gilead sciences inc gilead worldwide sales increases primarily due higher demand attributed successful launch atripla us july eu december canada october us prescription demand sustiva franchise increased approximately lesser extent higher average selling prices contributed increase net revenues baraclude oral antiviral agent treatment chronic hepatitis b worldwide sales increases primarily due continued growth across markets particularly international markets due successful launch various countries including china february uk germany july france japan september us april continues increased awareness acceptance longterm efficacy safety resistance data evidenced american association study liver disease treatment guidelines recommended baraclude first line treatment option erbitux monoclonal antibody designed exclusively target block epidermal growth factor receptor expressed surface certain cancer cells multiple tumor types well normal cells currently indicated use colorectal cancer head neck cancer erbitux part companys strategic alliance imclone sold company almost exclusively us sales increases primarily due increased demand recent indication usage treatment head neck cancer sales also positively impacted transition broader distribution model resulting higher sales associated initial shipments inventory distributors bristolmyers squibb taxol anticancer agent currently sold almost exclusively nonus markets sales decreases due primarily generic competition japan sprycel oral inhibitor multiple tyrosine kinases treatment adults chronic accelerated myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy including gleevec imatinib meslylate worldwide sales increases primarily due higher demand associated successful launch us july european markets beginning fourth quarter higher us selling prices continued launches russia turkey ixempra microtubule inhibitor treatment patients metastatic locally advanced breast cancer sales increase reflects launch product us october abilify antipsychotic agent treatment schizophrenia bipolar mania disorder major depressive disorder part companys strategic alliance otsuka pharmaceutical co ltd otsuka us sales increases primarily attributed increased demand higher average selling prices prescription demand increased approximately approximately contributing prescription growth new indications certain patients bipolar disorder major depressive disorder international sales increases also primarily attributed increased prescription demand sales growth aided new bipolar indication second quarter eu orencia fusion protein indicated adult patients moderate severe ra inadequate response one currently available treatments mtx antitumor necrosis factor therapy us sales increases primarily due continued growth since launch biologic product us february international sales increase reflects european launch may estimated us prescription change data provided throughout annual report includes information retail mail order channels reflect information channels hospitals institutions longterm care among others estimated prescription data based nextgeneration prescription service ngps version national prescription audit provided ims health ims supplier market research pharmaceutical industry described data provided ims product ims recordkeeping process estimate based ims sampling procedures data subject inherent limitations estimates based sampling may include margin error company calculated estimated total us prescription change based ngps data weightedaverage basis reflect fact mail order prescriptions include greater volume product supplied compared retail prescriptions mail order prescriptions typically reflect day prescription whereas retail prescriptions typically reflect day prescription calculation derived multiplying ngps mail order prescription data factor approximates three adding ngps retail prescriptions company believes calculation estimated total us prescription change based weightedaverage approach respect retail mail order channels provides superior estimate total prescription demand company uses methodology internal demand forecasts company continuously seeks improve quality estimates prescription change amounts ultimate patientconsumer demand review methodologies processes calculation estimates review analysis third parties data used calculations company expects continue review refine methodologies processes calculation estimates continue review analyze third parties data used calculations annual report estimated enduser demand following tables set forth companys key pharmaceutical products sold us pharmaceuticals business years ended december total us net sales period ii change reported us net sales period iii estimated total us prescription change retail mail order channels calculated company based ngps data weightedaverage basis iv months inventory hand wholesale distribution channel year ended december december change us change us months total us net sales net salesa total prescriptions b hand dollars millions plavix avaproavalide pravacholh reyataz sustiva franchise c baraclude erbitux na na na sprycel e ixemprad f na na na abilify orencia g na na na reflects percentage change net sales dollar terms b derived multiplying ngps mail order prescription data factor approximates three adding ngps retail prescriptions c beginning third quarter sustiva franchise total revenue includes sales sustiva well revenue bulk efavirenz included combination therapy atripla change us total prescriptions growth sustiva franchise includes branded sustiva atripla prescription units erbitux orencia ixempra parenterally administered products prescriptionlevel data physicians write prescriptions products e sprycel launched us july f ixempra launched us october g orencia launched us february h negative net sales attributed higher retail returns previously assumed change excess pursuant us securities exchange commission sec consent order described sec consent order company monitors level inventory hand us wholesaler distribution channel outside us direct customer distribution channel company obligated disclose products levels inventory excess one month hand expected demand subject de minimis exception following products estimated levels inventory distribution channel excess one month hand case companys us pharmaceuticals products december case companys international pharmaceuticals nutritionals products september september bufferin salicylatate drug approximately months inventory hand direct customers compared approximately months inventory hand december increased level inventory hand due primarily increased inventory levels china caused distributors preparations national holidays september dafalgan analgesic product sold principally europe approximately months inventory hand compared months inventory hand december previously stated level inventory hand september due primarily private pharmacists purchasing dafalgan approximately every eight weeks seasonality product september videxvidex ec antiviral product approximately months inventory hand direct customers compared months inventory hand december previously stated level inventory hand due primarily government purchasing patterns brazil company contractually obligated provide videxvidex ec brazilian government upon placement order product government terms contract company control inventory levels relating orders bristolmyers squibb us products sold exclusively wholesalers distributors company determines months hand estimates using information respect inventory levels product hand amount outmovement products provided companys three largest wholesalers accounted approximately total gross sales us pharmaceuticals products provided companys distributors factors may influence companys estimates include generic competition seasonality products wholesaler purchases light increases wholesaler list prices new product launches new warehouse openings wholesalers new customer stockings wholesalers addition estimates calculated using thirdparty data represent recordkeeping processes may also reflect estimates pharmaceutical products us sold exclusively wholesalers distributors companys pharmaceuticals business outside us nutritionals business units around world company significantly direct customers limited information direct customer product level inventory corresponding outmovement information reliability thirdparty demand information available varies widely cases direct customer product level inventory ultimate patientconsumer demand outmovement data exist otherwise available company developed variety methodologies calculate estimates data including using factors historical sales made direct customers thirdparty market research data related prescription trends enduser demand accordingly company relies variety methods estimate direct customer product level inventory calculate months hand business units factors may affect companys estimates include generic competition seasonality products direct customer purchases light price increases new product product presentation launches new warehouse openings direct customers new customer stockings direct customers expected direct customer purchases governmental bidding situations nutritionals composition change nutritional net sales follows vs vs net sales analysis change analysis change total foreign total foreign dollars millions change volume price exchange change volume price exchange us nonus total infant formulas toddlerchildrens nutritionals representing total nutritional net sales respectively follows net sales change dollars millions vs vs infant formulas enfamil toddlerchildrens nutritionals decrease us nutritional net sales primarily due decreased sales infant formulas increase international nutritionals net sales primarily due growth infant formulas childrens nutritionals increase us nutritional net sales primarily due increased sales infant formulas international nutritional net sales increased primarily due growth infant formulas childrens nutritionals annual report geographic areas general companys products available countries world largest markets us france spain canada china japan italy mexico germany companys sales geographic areas based location entity selling product follows net sales change total net sales vs vs dollars millions united states europe middle east africa western hemisphere pacific total see items previously discussed pharmaceuticals items impacting increase us net sales europe middle east africa sales increases primarily due sales growth major european markets abilify sprycel hiv hepatitis portfolio addition favorable foreign exchange impact sales essentially flat sales growth major european markets sprycel abilify hiv hepatitis portfolio favorable foreign exchange impact offset generic competition pravachol taxol western hemisphere countries sales essentially flat minimum foreign exchange impact sales increases primarily due increased sales plavix canada mexico key nutritional products avaproavalide canada favorable foreign exchange impact increases partially offset discontinued commercialization tequin pacific region sales increases primarily due sales growth baraclude china japan korea key nutritional products throughout region addition favorable foreign exchange impacts respectively addition sales negatively impacted increased generic competition taxol pravachol single country outside us contributed companys total revenues net sales france canada spain japan exceeded million net sales china italy exceeded million mexico million sales bristolmyers squibb expensesgains change net sales vs vs dollars millions costs products sold marketing selling administrative advertising product promotion research development acquired inprocess research development provision restructuring net litigation expense net gain sale product lines businesses equity net income affiliates gain sale imclone shares expense net total expenses net change excess costs products sold improvement costs products sold percentage net sales primarily attributed favorable worldwide pharmaceuticals product sales mix higher us pharmaceuticals average selling prices realized manufacturing savings pti factors partially offset product material price increases costs include manufacturing rationalization charges million related implementation pti net sales compared million rationalization charges recorded net sales improvement costs products sold percentage sales primarily due sales growth higher margin products including plavix marketing selling administrative increase primarily related million increased process standardization costs incurred part pti compared prior period million costs incurred part initial public offering mead johnson higher selling expenses support key products unfavorable foreign exchange impact increase primarily due unfavorable impact foreign exchange higher marketing expenses partially offset lower sales force expenses decrease marketing selling administrative expenses percentage net sales result increased sales growth outpacing expenses managed pti advertising product promotion increase primarily related increased promotions new indications abilify us increased promotion orencia increased expenses international nutritionals business unfavorable foreign exchange impact increase primarily related increased spending directtocustomer advertising plavix abilify orencia expenses support launch ixempra higher spending newer products europe unfavorable foreign exchange impact annual report research development increase primarily related increased licensing upfront milestone payments increased spending pipeline compounds unfavorable foreign exchange impact increase partially offset sharing codevelopment costs alliance partners astrazeneca pfizer increase primarily attributed continued investment latestage compounds developing pipeline disease areas address significant unmet medical needs well increased upfront milestone payments compared detailed increase partially offset sharing codevelopment costs alliance partners astrazeneca pfizer upfront milestone payments made expensed research development totaled million paid primarily exelixis pdl biopharma inc kai charges totaled million paid exelixis pfizer adnexus therapeutics inc adnexus isis charges totaled million paid exelixis solvay global research development expenses dedicated pharmaceutical products pharmaceutical net sales respectively acquired inprocess research development acquired inprocess research development costs iprd consisted estimated fair value research development acquired part acquisition december immediately expensed acquisition date charge related iprd acquisition kosan whereas charge related iprd obtained acquisition adnexus provision restructuring net increase provision restructuring net attributed timing implementation pti announced december expanded july increase attributed charges primarily severance related associated announcement pti december see note restructuring litigation expense net litigation expenses related reserves settlement principle certain pricing sales investigations partially offset insurance recoveries unrelated matter positive settlement litigation matter additional information litigation matters see note legal proceedings contingencies gain sale product lines businesses gain primarily attributable sale mature brands businesses egypt gain attributed sale bufferin excedrin brands japan asia excluding china taiwan certain oceanic countries well certain assets related us dermatology products gain attributed sale inventory patent intellectual property rights related dovonex additional information transactions see note acquisitions divestitures equity net income affiliates equity net income affiliates principally related companys international joint venture sanofi increases correlated increases international plavix sales additional information equity net income affiliates see note alliances collaborations gain sale imclone shares gain sale imclone shares attributed companys receipt approximately billion cash tendering investment imclone see note alliances collaborations detail bristolmyers squibb expense net components expense net follows year ended december dollars millions interest expense interest income ars impairment charge gainloss debt buyback termination interest rate swap agreements foreign exchange transaction gainslosses net expense net interest expense decreases primarily due decreases interest rates interest income relates primarily interest earned cash cash equivalents investments marketable securities decrease interest income primarily due change mix companys shortterm investment portfolio well decrease rate return shortterm investments including us treasury bills compared prior year ars impairment charge attributed companys auction rate securities ars addition million loss sale ars recognized included net see note cash cash equivalents marketable securities detail gain debt buyback attributed repurchase certain debt monetization certain interest rate swaps due recent appreciation value see note shortterm borrowing longterm debt information foreign exchange transaction gains attributed strengthening us dollar impact nonqualifying foreign exchange hedges remeasurement nonfunctional currency denominated transactions compared prior year net includes income thirdparty contract manufacturing certain royalty income expense debt retirement costs gains losses sale property plant equipment gains losses sale marketable securities insurance recoveries deferred income recognized certain litigation matters convatec medical imaging net transitional service fees amortization certain upfront payments related companys alliances proceeds swap terminations pension curtailments see note expense net information annual report years ended december company recorded following specified expenseincome items affected comparability results periods presented herein discussion items see note alliances collaborations note restructuring note acquisitions divestitures note income taxes note cash cash equivalents marketable securities note shortterm borrowings longterm debt note legal proceedings contingencies acquired gain marketing inprocess provision sale gain year ended december cost selling research research litigation product sale products restructuring expense lines imclone expense dollars millions sold administrative development development net net businesses shares net total productivity transformation initiative downsizing streamlining worldwide operations accelerated depreciation asset impairment shutdown costs pension settlementscurtailments process standardization implementation costs gain sale leaseback properties termination lease contracts gain sale product lines businesses litigation settlement insurance recovery mead johnson charges product liability upfront milestone payments acquired inprocess research development asset impairment ars impairment charges loss sale debt buyback swap terminations gain sale imclone shares income taxes items decrease net earnings continuing operations bristolmyers squibb marketing acquired provision gain sale year ended december cost selling research inprocess litigation product products research restructuring expense lines expense dollars millions sold administrative development development net net businesses net total productivity transformation initiative downsizing streamlining worldwide operations accelerated depreciation asset impairment process standardization implementation costs litigation settlement insurance recovery product liability upfront milestone payments acquired inprocess research development ars impairment charges downsizing streamlining worldwide operations accelerated depreciation asset impairment contract termination gain sale properties product lines businesses income taxes items change estimate taxes prior year specified item decrease net earnings continuing operations gain sale year ended december cost marketing research provision litigation product products selling restructuring expense lines expense dollars millions sold administrative development net net businesses net total litigation matters pharmaceutical pricing sales litigation product liability claim damages commercial litigations insurance recovery debt retirement costs accelerated depreciation asset impairment contract termination upfront milestone payments downsizing streamlining worldwide operations gain sale product lines businesses income taxes items change estimate taxes prior year specified items decrease net earnings continuing operations specified items presented reflected segment results follows dollars millions pharmaceuticals nutritionals total segments corporateother total includes million gain sale imclone shares annual report earnings continuing operations income taxes minority interest earnings continuing operations income taxes minority interest change segment net sales vs vs dollars millions pharmaceuticals nutritionals total segments corporateother total pharmaceuticals earnings increased primarily due increased sales plavix abilify hiv hepatitis portfolio orencia increase segment income percentage segment net sales primarily due similar factors discussed analysis consolidated expenses favorable product sales mix higher average selling prices realized manufacturing savings pti contributed reduction costs products sold percentage net sales results pti also contributed reduction marketing selling administrative expense percentage net sales earnings increased primarily due increased plavix sales strong sales growth key products increase segment income percentage segment net sales similar reasons discussed although lesser extent pti beginning nutritionals earnings increased primarily due increased international net sales increase segment income percentage segment net sales primarily due growth rate net sales exceeding growth rate marketing selling administrative expenses research development well bad debt charge distributor insolvency factors partially offset higher dairy prices advertising promotion expenses additional legal accounting consulting expenses incurred preparation initial public offering earnings increased primarily due growth key products decrease segment income percentage segment net sales primarily due higher dairy prices unfavorable product mix bad debt charge distributor insolvency corporateother earnings continuing operations income taxes minority interest reported corporateother consists dollars millions corporate administrative expense stockbased compensation expense provision restructuring net litigation expense net interest expense interest income ars impairment charge gain sale imclone shares gain sale product lines businesses gainloss debt buyback termination interest rate swap agreements total corporateother earnings continuing operations income taxes minority interest bristolmyers squibb income taxes effective income tax rate earnings continuing operations income taxes minority interest compared increase effective tax rate primarily due higher pretax income us including gain sale imclone earnings mix high tax jurisdictions partially offsetting impacts lower nondeductible charges acquired inprocess research development expenses lower ars impairment charges little tax benefit tax rate favorably impacted benefit million tax related final settlement audit internal revenue service tax rate unfavorably impacted impairment companys investment certain ars little tax benefit nondeductible writeoff acquired inprocess research development expenses related acquisition adnexus partially offset tax benefit million first quarter due favorable resolution certain tax matters internal revenue service related deductibility litigation settlement expenses us foreign tax credits claimed effective tax rate unfavorably impacted elimination tax benefits section internal revenue code treatment provisions portion certain litigation reserves nondeductible partially offset favorable us tax legislation enacted related tax treatment certain intercompany transactions amongst companys foreign subsidiaries implementation tax planning strategies related utilization certain charitable contributions company recognized significant deferred tax assets december related us federal foreign tax credit carryforwards approximately million us federal research development tax credit carryforwards approximately million us federal charitable contribution carryforwards fully utilized due gains related convatec medical imaging divestitures foreign tax credit research development tax credit carryforwards expire varying amounts beginning foreign tax credit research development tax credit carryforwards reduced due derecognition fin convatec medical imaging divestitures resulted significant reduction foreign tax credit research development tax credit carryforwards realization foreign tax credit research development tax credit carryforwards dependent generating sufficient domesticsourced taxable income prior expiration although realization assured management believes likely deferred tax assets realized minority interest minority interest primarily related companys partnership sanofi territory covering americas related plavix sales increases minority interest correspond increased sales plavix dollars millions sanofi partnership others minority interest pretax income taxes minority interest net taxes financial position liquidity capital resources company continues maintain sufficient level working capital approximately billion december billion december future periods company expects cash generated us operations together existing cash cash equivalents marketable securities borrowings capital markets sufficient cover cash needs working capital capital expenditures company expects include investments facilities increase maintain companys capacity provide biologics commercial scale strategic alliances acquisitions milestone payments dividends paid us cash cash equivalents marketable securities conversion working capital items borrowings expected fund nearterm operations outside us december company obtained billion five year revolving credit facility syndicate lenders extendable anniversary date consent lenders facility contains customary terms conditions including financial covenant whereby ratio consolidated debt consolidated capital exceed end quarter company compliance covenant since inception new facility borrowings outstanding revolving credit facility december february mead johnson entered three year syndicated revolving credit facility agreement credit facility unsecured provides borrowings letters credit million annual report net financial assets net financial asset position december follows dollars millions financial assets cash cash equivalents marketable securitiescurrent total financial assets debt shortterm borrowings including current portion longterm debt longterm debt total debt net cashdebt net cashdebt net cashdebt position december improved due proceeds billion divestiture convatec medical imaging businesses proceeds billion sale imclone shares cash generated operating activities billion adequate fund dividend payments billion well capital expenditure payments million investments following table summarizes companys carrying value related unrealized lossgain position current noncurrent marketable securities include us dollardenominated floating rate securities frs ars accounted available sale debt securities see note cash cash equivalents marketable securities discussion company frs ars portfolio including related cost basis fair value investment deceber decemb er decemb er unrealized unrealized lossgain carrying lossgain dollars millions carrying value accumulated oci value accumulated oci current available sale floating rate securities us treasury bills total current noncurrent available sale auction rate securities floating rate securities total noncurrent company received million principal par primarily frs matured march temporarily reduced carrying value remaining frs million million unrealized loss accumulated comprehensive income oci addition company reclassified million remaining frs maturity dates beyond current assets noncurrent assets due liquidity concerns continued uncertainty capital markets company received million primarily connection sale ars carrying value million resulting loss million addition million otherthantemporary impairment charge recognized including million previously determined temporary december impairment charge required analysis otherthantemporary impairment factors including severity duration decline value future prospects issuer companys ability intent hold securities recovery ars sold securities generally backed sub prime mortgages collateralized debt obligations structured credit ars remaining december represents interests insurance securitizations lesser extent structured credit uncertainties credit capital markets continue markets deteriorate company experiences additional ratings downgrades investments portfolio including frs ars company may incur additional impairments bristolmyers squibb investment portfolio could negatively affect companys financial condition reported earnings company believes based companys current level cash cash equivalents marketable securities expected operating cash flows current lack liquidity credit capital markets material impact companys liquidity cash flow financial flexibility ability fund operations including dividend credit ratings moodys investors service moodys longterm shortterm credit ratings company currently prime respectively moodys revised longterm credit rating outlook negative stable standard poors sp longterm short term credit ratings company currently respectively sps longterm credit rating remains stable outlook fitch ratings fitch longterm shortterm credit ratings company currently f respectively fitchs longterm credit rating remains stable outlook working capital following discussion working capital decem ber dollars millions working capital increase working capital billion december december impacted proceeds sale convatec business billion proceeds sale imclone shares billion proceeds issuance notes due billion notes due million cash flows following discussion cash flow activities years ended december dollars millions cash flow provided byused operating activities investing activities financing activities operating activities cash flow operating activities represents cash receipts cash disbursements related activities company investing activities financing activities operating cash flow derived adjusting net earnings noncash operating items depreciation amortization impairment charges stockbased compensation charges gains losses attributed investing financing activities gains losses sale product lines businesses changes operating assets liabilities reflect timing differences receipt payment cash associated transactions recognized results operations companys operating cash flow grown consistently throughout three years ended december increases net income attributed reasons noted throughout mda continue directly impact operating cash flows evident net income adjusted noncash operating items well gains losses attributed investing financing activities amounted billion billion billion amounts exclude changes operating assets liabilities discussed annual report net impact changes operating assets liabilities discussed detail include impact changes receivables inventories deferred income accounts payable income taxes receivablepayable operating assets liabilities company continues maximize operating cash flows recently announced working capital initiative designed continue improve working capital items directly affected changes sales volume accounts receivable inventories accounts payable changes operating assets resulted net cash inflow million impacted cash inflows income tax payablereceivable million includes impact receipt million tax refund including interest related prior year foreign tax credit carryback claim cash inflows accounts payables million primarily attributed timing vendor alliance payments cash inflows inventory million primarily attributed utilization inventories built prior year new product launches strategic builds existing products launches including new indications abilify cash inflows deferred income million primarily due receipt upfront milestone payments alliance partners cash outflows operating assets liabilities million primarily due net litigation related payments made current period million attributed settlement certain pricing sales litigation accrued prior periods pension funding excess current year expense million increase noncurrent inventory million cash outflows accounts receivables million attributed increased sales changes operating assets resulted net cash outflow million impacted cash outflows accounts receivable million primarily attributed increased sales cash outflows us foreign income taxes payable million primarily attributed tax payments included settlement payments associated various tax issues irs audit cash inflows deferred income million primarily due receipt upfront milestone payments alliance partners including pfizer astrazeneca cash inflows operating assets liabilities million primarily due increases accrued royalties attributed increased plavix sales increases accrued salaries bonuses due timing payments partially offset cash outflows primarily related litigation related payments million settlement pricing sales litigation accrued prior periods cash inflows accounts payables million include impact increased purchases raw materials planned inventory buildup changes operating assets resulted net cash outflow million impacted cash outflows operating assets liabilities million primarily due pay accrued rebates returns primarily resulting exclusivity loss pravachol volume erosion highly rebated paraplatin taxol lower plavix volumes reduced royalties lower plavix sales additions litigation settlement accrual related pricing sales litigation settlements primarily offset net litigation related payments related matters accrued prior years million cash outflows accounts payable million primarily due lower purchases pravachol raw materials due loss pravachol exclusivity significant reduction payables early resulting lower payment invoices december cash inflows accounts receivables million primarily due lower plavix sales loss exclusivity pravachol bristolmyers squibb investing activities net cash provided investing activities billion included proceeds divestiture convatec billion medical imaging million mature brands business egypt million proceeds tendering companys shares imclone billion proceeds sale leaseback paris france facility million capital expenditures million included expenditures associated construction companys biologic facility devens massachusetts acquisition kosan million net cash used investing activities million included capital expenditures million acquisition adnexus million net proceeds sale marketable securities million proceeds sales bufferin excedrin brands japan asia excluding china taiwan certain oceanic countries us dermatology products million net cash provided investing activities million included net proceeds sale marketable securities million proceeds disposal properties connection sale lease back administrative facilities new jersey million proceeds sale various product assets primarily sale several assets related dovonex million capital expenditures million milestone payments primarily related imclone million financing activities net cash used financing activities billion included dividend payments billion redemption floating rate convertible senior debentures due billion repayment notes due august million yen notes due million repurchase companys notes million net proceeds issuance notes due million notes due billion net proceeds termination interest rate swap agreements million net proceeds stock option exercises million reflects exercise fewer stock options due decrease average stock price compared prior periods net cash used financing activities billion included dividend payments billion repayment floating rate bank facility billion proceeds exercise stock options million net cash used financing activities billion included debt payments associated early retirement notes due billion floating rate bank facility billion dividend payments billion proceeds issuance notes due billion euro notes billion annual report dividends declared per common share december company declared quarterly dividend per common share indicated dividend full year per share dividend decisions made quarterly basis companys board directors contractual obligations payments due period companys contractual obligations december follows obligations expiring period dollars millions total later years shortterm borrowings longterm debt interest longterm debt operating leases purchase obligations standby letters creditperformance guarantees uncertain tax positions longterm liabilities total current portion longterm debt obligations included shortterm borrowings companys consolidated balance sheet december balances approximate outstanding nominal longterm debt values includes estimated future interest payments shortterm longterm debt also includes accrued interest payable recorded consolidated balance sheets consists primarily accrual interest shortterm longterm debt well accrual periodic cash settlements derivatives netted counterparty due uncertainty related timing reversal uncertain tax positions shortterm uncertain tax benefits provided table include minority interest million table excludes future contributions company pension postretirement postemployment benefit plans required contributions contingent upon numerous factors including minimum regulatory funding requirements funded status plan due uncertainty future obligations excluded table contributions us international plans expected million see note pension postretirement postemployment benefits detail addition company committed make approximately billion potential future research development milestone payments third parties part inlicensing development programs payments agreements generally become due payable upon achievement certain developmental regulatory milestones specific timing predicted achievement milestones neither probable reasonably estimable contingencies recorded companys consolidated balance sheets discussion contractual obligations see note shortterm borrowings longterm debt note financial instruments note leases note pension postretirement postemployment liabilities sec consent order previously disclosed august company entered final settlement sec concluding investigation concerning certain wholesaler inventory accounting matters settlement reached consent copy attached exhibit companys quarterly report form q period ended september terms consent company agreed subject certain defined exceptions limit sales products sold direct customers including wholesalers distributors hospitals retail outlets pharmacies government purchasers based expected demand amounts exceed approximately one month inventory hand without making timely public disclosure change practice company also agreed consent certain measures implemented including establishing formal review certification process annual quarterly reports filed sec b establishing business risk disclosure group c retaining outside consultant comprehensively study help reengineer companys accounting financial reporting processes publicly disclosing sales incentives offered direct customers purpose inducing purchase products excess expected demand e ensuring companys budget process gives appropriate weight inputs come bottom top top bottom adequately documenting process bristolmyers squibb company established companywide policy limit sales direct customers purpose complying consent policy includes adoption various procedures monitor limit sales direct customers accordance terms consent procedures include governance process escalate appropriate management levels potential questions concerns regarding compliance policy timely resolution questions concerns addition compliance policy monitored regular basis company maintains inventory management agreements imas us pharmaceutical wholesalers account nearly total gross sales us pharmaceutical products current terms imas companys three largest wholesaler customers provide company weekly information respect months hand productlevel inventories amount outmovement products three wholesalers currently account approximately total gross sales us pharmaceuticals products inventory information received wholesalers together companys internal information used estimate months hand product level inventories wholesalers company estimates months hand product inventory levels us pharmaceutical businesss wholesaler customers three largest wholesalers extrapolating months hand calculated three largest wholesalers contrast companys pharmaceutical business outside us nutritionals business units around world company significantly direct customers limited information direct customer product level inventory corresponding outmovement information reliability thirdparty demand information available varies widely accordingly company relies variety methods estimate months hand product level inventories business units company believes abovedescribed procedures provide reasonable basis ensure compliance consent recently issued accounting standards following new accounting pronouncements critical companys financial statements discussed note acounting policiesrecently issued accounting standards considered evaluated required application impact eitf issue accounting nonrefundable advance payments goods services received use future research development activities sfas fair value option financial assets financial liabilities sfas fair value measurements sfas disclosures derivative instruments hedging activities eitf issue accounting collaborative arrangements related development commercialization intellectual property sfas noncontrolling interests consolidated financial statementsan amendment arb sfas r business combinations critical accounting policies company prepares financial statements conformity accounting principles generally accepted us preparation financial statements conformity us generally accepted accounting principles gaap requires use estimates assumptions affect reported amounts assets liabilities including disclosure contingent assets contingent liabilities date financial statements reported amounts revenue expenses reporting period companys critical accounting policies important companys financial condition results operations require difficult subjective complex judgments part management application often result need make estimates effect matters inherently uncertain uncertainty factors surrounding estimates judgments used preparation consolidated financial statements actual results may vary estimates company believes following discussion represents critical accounting policies management discussed companys critical accounting policies audit committee board directors revenue recognition company recognizes revenue accordance staff accounting bulletin sab revenue recognition financial statements amended sab revenue recognition companys accounting policy revenue recognition substantial impact reported results relies certain estimates require difficult subjective complex judgments part management company recognizes revenue net grosstonet sales adjustments discussed involve significant estimates judgments title substantially risks rewards ownership transferred customer generally occurs date shipment annual report case new products product introduction extension existing line product company determines products similar therapeutic category company determines new product dissimilar characteristics existing products company reliably estimate expected returns new product company defers recognition revenue right return longer exists company developed sufficient historical experience estimate sales returns discussions revenue recognition see note accounting policiesrevenue recognition sales rebate return accruals grosstonet sales adjustments company following significant categories grosstonet sales adjustments prime vendor chargebacks wic rebates managed health care rebates contract discounts medicaid rebates cash discounts sales returns adjustments involve significant estimates judgments require company use information external sources company accounts grosstonet sales adjustments accordance eitf issue accounting consideration given vendor customer including reseller vendors products sfas revenue recognition right return exists applicable see net sales section reconciliation companys gross sales net sales significant category grosstonet sales adjustment prime vendor chargebacks companys us businesses participate prime vendor programs government entities significant us department defense us department veterans affairs parties whereby pricing products extended wholesaler list price participating entities entities purchase products wholesalers lower prime vendor price wholesalers charge difference acquisition cost lower prime vendor price back company company accounts prime vendor chargebacks reducing accounts receivable amount equal companys estimate chargeback claims attributable sale company determines estimate prime vendor chargebacks primarily based historical experience regarding prime vendor chargebacks current contract prices prime vendor programs company considers prime vendor payments levels inventory distribution channel companys claim processing time lag adjusts reduction accounts receivable periodically throughout quarter reflect actual experience wic rebates companys us nutritionals business participates competitive bidding basis nutrition programs sponsored states tribal governments commonwealth puerto rico us territories women infants children wic programs company reimburses entities difference wholesaler list price contract price eligible products company accounts wic rebates establishing accrual amount equal companys estimate wic rebate claims attributable sale company determines estimate wic rebate accrual primarily based historical experience regarding wic rebates current contract prices wic programs company considers levels inventory distribution channel new wic contracts terminated wic contracts changes existing wic contracts wic participation adjusts accrual periodically throughout quarter reflect actual experience managed health care rebates contract discounts company offers rebates discounts managed health care organizations us manage prescription drug programs medicare advantage prescription drug plans covering medicare part drug benefit addition commercial plans well globally contract counterparties hospitals group purchasing organizations addition company pays rebates us department defense tricare retail pharmacy refund program company accounts managed health care rebates contract discounts establishing accrual amount equal companys estimate managed health care rebates contract discounts attributable sale company determines estimate managed health care rebates contract discounts accrual primarily based historical experience regarding rebates discounts current contract prices company considers sales performance products subject managed health care rebates contract discounts levels inventory distribution channel adjusts accrual periodically throughout quarter reflect actual experience bristolmyers squibb medicaid rebates companys us businesses participate state governmentmanaged medicaid programs well certain qualifying federal state government programs whereby discounts rebates provided participating state local government entities discounts rebates provided latter programs included companys medicaid rebate accrual considered medicaid rebates purposes discussion company accounts medicaid rebates establishing accrual amount equal companys estimate medicaid rebate claims attributable sale company determines estimate medicaid rebates accrual primarily based historical experience regarding medicaid rebates well expansion prospective basis participation nonmandatory aspects qualifying federal state government programs legal interpretations applicable laws related medicaid qualifying federal state government programs new information regarding changes medicaid programs regulations guidelines would impact amount rebates company considers outstanding medicaid claims medicaid payments levels inventory distribution channel adjusts accrual periodically throughout quarter reflect actual experience cash discounts us certain countries company offers cash discounts approximating sales price incentive prompt payment company accounts cash discounts reducing accounts receivable full amount discounts company considers payment performance adjusts accrual reflect actual experience sales returns company accounts sales returns accordance sfas revenue recognition right return exists establishing accrual amount equal companys estimate sales recorded related products expected returned provision sales returns million million million approximates gross sales three years returns established products company determines estimate sales return accrual primarily based historical experience regarding sales returns also considers factors could impact sales returns factors include levels inventory distribution channel estimated shelf life product recalls product discontinuances price changes competitive products introductions generic products introductions competitive new products company considers factors adjusts accrual periodically throughout quarter reflect actual experience event product recall product discontinuance company considers reasons impact actions adjusts sales return accrual appropriate taking account historical experience estimated levels inventory distribution channel product discontinuances estimates continuing demand sales returns accruals new products estimated primarily based historical sales returns experience similar products within line product within similar therapeutic category limited circumstances new product extension existing line product company historical experience products similar therapeutic category company reliably estimate expected returns new product company defers recognition revenue right return longer exists company developed sufficient historical experience estimate sales returns company also considers shelf life new products determines whether believes adjustment sales return accrual appropriate shelf life connection new products tends shorter shelf life established products company may still developing optimal manufacturing process new product would lengthen shelf life addition higher launch quantities may manufactured advance launch date ensure sufficient supply exists satisfy market demand cases company assesses reduced shelf life together estimated levels inventory distribution channel projected demand determines whether believes adjustment sales return accrual appropriate adjustments addition grosstonet sales adjustments described company makes grosstonet sales adjustments example company offers sales discounts significantly nonus businesses also offers consumer coupons rebates significantly us nutritionals pharmaceuticals businesses addition number countries outside us including certain major european countries company provides rebates government entities company generally accounts grosstonet adjustments establishing accrual amount equal companys estimate adjustments attributable sale company generally determines estimates accruals grosstonet sales adjustments primarily based historical experience performance commitments government entities relevant factors including estimated levels inventory distribution channel adjusts accruals periodically throughout quarter reflect actual experience annual report use information external sources company uses information external sources estimate grosstonet sales adjustments companys estimates inventory wholesalers based projected prescription demandbased sales products historical inventory experience well companys analysis thirdparty information including written oral information obtained certain wholesalers respect inventory levels sellthrough customers thirdparty market research data companys internal information inventory information received wholesalers product recordkeeping process excludes inventory held intermediaries sell retailers hospitals company receives information ims supplier market research pharmaceutical industry uses project prescription demandbased sales many us pharmaceutical products ims refined improved ngps projection methodology fully rolled ngps version national prescription audit subscribers resulted newly revised volume estimates historic time periods therefore since first quarter company used new ims standard ngps version projection methodology applied ngps version data reporting prescription growth market shares periods presented annual report company also continued practice combining retail mail prescription volume retailequivalent basis company uses methodology internal demand forecasts company also uses information external sources identify prescription trends patient demand average selling prices companys estimates subject inherent limitations estimates rely thirdparty information certain thirdparty information form estimates reflect limitations including lags date thirdparty information generated date company receives thirdparty information retirement benefits companys pension plans postretirement benefit plans accounted using actuarial valuations management required make significant subjective judgments number actuarial assumptions including discount rates salary growth longterm return plan assets retirement turnover health care cost trend rates mortality rates depending assumptions estimates used pension postretirement benefit expense could vary within range outcomes material effect reported earnings addition assumptions materially affect projected benefit obligations future cash funding company adopted sfas employers accounting defined benefit pension postretirement plansan amendment fasb statements r year ended december adoption accounting pronouncement resulted billion reduction accumulated comprehensive income stockholders equity million reduction total assets million increase total liabilities adoption sfas impact companys results operations cash flows companys key assumptions used calculating cost pension benefits discount rate rate compensation increase expected longterm rate return plan assets company consultation actuaries evaluates key actuarial assumptions assumptions used calculating cost pension benefits retirement turnover mortality rates based expectations actual experience appropriate determines assumptions december year calculate liability information date pension expense following year depending assumptions used pension expense could vary within range outcomes material effect reported earnings addition assumptions materially affect projected benefit obligations future cash funding actual results given year may differ estimated economic factors determining discount rate company uses yield high quality corporate bonds coincides cash flows plans estimated payouts citigroup median yield curve used determining discount rate us plans assumed rate compensation increase used company determining future pension obligations reflects estimate change actual future compensation levels due general price levels productivity seniority factors us plans pension expense determined using assumed discount rate assumed rate compensation increase present value benefit obligations december us plans determined using assumed discount rate assumed rate compensation increase assumed discount rate used determining us plans pension expense reduced expense would increased approximately million assumed rate compensation increase used determining us plans pension expense reduced expense would decreased approximately million assumed discount rate used determining projected benefit obligation december reduced projected benefit obligation would increased million determining expected longterm rate return plan assets company estimates returns individual asset classes input external advisors company also considers longterm historical returns including actual performance compared benchmarks similar investments bristolmyers squibb us plans pension expense determined using expected longterm rate return plan assets expected longterm rate return plan assets used determining us plans pension expense reduced expense would increased million detailed discussion retirement benefits see note pension postretirement postemployment liabilities acquisitions companys consolidated financial statements results operations reflect acquired business completion acquisition acquired businesses accounted using purchase method accounting requires purchase price allocated net assets acquired respective fair values excess purchase price estimated fair values net assets acquired recorded goodwill amounts allocated acquired iprd expensed date acquisition judgments made determining estimated fair value assigned class assets acquired liabilities assumed well asset lives materially impact results operations several methods used determine fair value assets acquired liabilities assumed intangible assets including iprd typically use income method method starts forecast expected future net cash flows cash flows adjusted present value applying appropriate discount rate reflects risk factors associated cash flow streams significant estimates assumptions inherent income method methods include amount timing projected future cash flows amount timing projected costs develop iprd commercially viable products discount rate selected measure risks inherent future cash flows assessment assets life cycle competitive trends impacting asset including consideration technical legal regulatory economic barriers entry well expected changes standards practice indications addressed asset determining useful life intangible asset also requires judgment different types intangible assets different useful lives example useful life right associated pharmaceutical products exclusive patent finite result amortization expense recognized results operations determinable period detailed discussion acquired inprocess research development see note accounting policiesacquired inprocess research development impairment longlived assets company periodically evaluates whether current facts circumstances indicate carrying value depreciable assets held used may recoverable circumstances determined exist estimate undiscounted future cash flows produced longlived asset appropriate grouping assets compared carrying value determine whether impairment exists asset determined impaired loss measured based difference assets fair value carrying value estimate assets fair value based quoted market prices active markets available quoted market prices available estimate fair value based various valuation techniques including discounted value estimated future cash flows company reports asset disposed lower carrying value estimated net realizable value goodwill tested least annually impairment using twostep process first step identify potential impairment second step measures amount impairment loss goodwill deemed impaired carrying amount reporting units goodwill exceeds estimated fair value longlived assets tested impairment using onestep process consists comparison fair value carrying value asset assets deemed impaired net book value exceeds estimated fair value estimates future cash flows based reasonable supportable assumptions projections require managements judgment changes key assumptions companys businesses prospects changes market conditions could result impairment charge impairment charges longlived assets million million million discussions impairment longlived assets see note accounting policiesimpairment longlived assets goodwill intangible assets annual report equity investments company reviews equity investments impairment based determination whether decline market value investment companys carrying value temporary making determination company considers apb opinion equity method accounting investments common stock related interpretations set forth factors evaluated determining whether loss value recognized including companys ability hold investment market price market price fluctuations investments publicly traded shares inability investee sustain earnings capacity would justify carrying amount investment companys previous investment imclone subject accounting discussion companys investment imclone see note alliances collaborations discussions equity investments see note accounting policiesinvestments note alliances collaborations marketable securities companys marketable securities december consisted us treasury bills frs ars due lack availability observable market quotes companys investment portfolio frs ars company utilizes valuation models including based expected cash flow streams collateral values including assessments counterparty credit quality default risk underlying security discount rates overall capital market liquidity valuation subject uncertainties difficult predict factors may impact companys valuation include changes credit ratings securities well underlying assets supporting securities rates default underlying assets underlying collateral value discount rates counterparty risk ongoing strength quality market credit liquidity considerable amount judgment estimation applied valuation frs ars addition company also applies judgment determining whether marketable securities otherthantemporarily impaired company typically considers severity duration decline future prospects issuer companys ability intent hold security recovery otherthantemporary impairment charges related ars million million respectively carrying value ars million december credit capital markets continued deteriorate uncertainties markets continue markets deteriorate company experiences additional ratings downgrades investments portfolio including ars company may incur additional impairment charges discussions marketable securities frs ars see note fair value measurement note cash cash equivalents marketable securities restructuring streamline operations rationalize manufacturing facilities company periodically recorded restructuring charges result company made estimates judgments regarding future plans including future termination benefits exit costs incurred restructuring actions take place actual results could vary estimates adjustments reflect changes estimates restructuring actions taken prior periods resulted increase million reduction million million discussions restructuring see note accounting policiesrestructuring note restructuring contingencies normal course business company subject contingencies legal proceedings claims arising business cover wide range matters including among others government investigations shareholder lawsuits product environmental liability accordance sfas accounting contingencies company records accruals contingencies probable liability incurred amount loss reasonably estimated estimates subject uncertainties difficult predict actual results could vary estimates discussions contingencies see note accounting policiescontingencies note income taxes note legal proceedings contingencies bristolmyers squibb income taxes provision income taxes determined using asset liability approach accounting income taxes approach deferred taxes represent future tax consequences expected occur reported amounts assets liabilities recovered paid provision income taxes represents income taxes paid payable current year plus change deferred taxes year deferred taxes result differences financial tax bases companys assets liabilities adjusted changes tax rates tax laws changes enacted valuation allowances recorded reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecast future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made company net deferred tax assets billion billion december respectively net valuation allowances billion billion company recognized significant deferred tax assets december related us federal foreign tax credit carryforwards million us federal research development tax credit carryforwards million realization tax credit carryforwards dependent generating sufficient domesticsourced taxable income prior expiration although realization assured management believes likely deferred tax assets realized company establishes liabilities possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known discussions income taxes see note accounting policiesincome taxes note income taxes special note regarding forwardlooking statements annual report written oral statements company makes time time contain certain forwardlooking statements within meaning section securities act section e securities exchange act identify forwardlooking statements fact use words expect anticipate estimate target may project guidance intend plan believe words terms similar meaning expression connection discussion future operating financial performance one also identify forwardlooking statements fact relate strictly historical current facts forwardlooking statements based current expectations involve inherent risks uncertainties including factors could delay divert change could cause actual outcomes differ materially current expectations statements likely relate among things companys goals plans projections regarding financial position results operations cash flows market position product development product approvals sales efforts expenses performance results current anticipated products outcome contingencies legal proceedings financial results based current expectations involve inherent risks uncertainties including internal external factors could delay divert change next several years company included important factors cautionary statements included annual report company believes could cause actual results differ materially forward looking statement although company believes prudent plans assumptions assurance given goal plan set forth forwardlooking statements achieved readers cautioned place undue reliance statements speak date made company undertakes obligation release publicly revisions forwardlooking statements result new information future events otherwise annual report quantitative qualitative disclosures market risk company exposed market risk due changes currency exchange rates interest rates lesser extent natural gas pricing reduce risk company enters certain derivative financial instruments available costeffective basis hedge underlying economic exposure companys primary net foreign currency translation exposures euro japanese yen canadian dollar chinese renminbi mexican peso manage exposures company utilizes foreign currency contracts subject cash flow hedge accounting treatment instruments managed consolidated basis efficiently net exposures thus take advantage natural offsets company also uses derivative instruments part interest rate risk management strategy derivative instruments used comprised principally fixedtofloating rate interest swaps subject fairvalue hedge accounting treatment addition companys financial instruments including derivatives subject counterparty credit risk company considers part overall fair value measurement derivative financial instruments used speculative purposes foreign exchange risk significant portion companys revenues earnings exposed changes foreign currency rates addition company exposed foreign exchange transaction risk arises nonfunctional currency denominated assets liabilities order manage risk company uses foreign exchange forward contracts offset exposure certain assets liabilities earnings denominated certain foreign currencies foreign exchange forward contracts designated hedges therefore changes fair value derivatives recognized earnings expense net occur addition company utilizes foreign currency contracts manage foreign exchange risk primarily arises certain intercompany transactions designates derivative instruments foreign currency cash flow hedges appropriate notional amounts companys foreign exchange derivative contracts billion billion december respectively derivatives majority qualify hedges future anticipated cash flows effective portion changes fair value temporarily deferred accumulated oci recognized earnings hedged item affects earnings company estimates appreciation depreciation underlying currencies hedged levels us dollar december variables held constant would decrease million increase million respectively fair value foreign exchange forward contracts held december company also exposed translation risk nonus dollardenominated net assets order manage risk company uses nonus dollar borrowings primarily million notes due million notes due hedge foreign currency exposures companys net investment certain foreign affiliates nonus dollar borrowings designated hedges net investments effective portion foreign exchange gains losses hedges recorded part foreign currency translation component accumulated oci additional information see note financial instruments interest rate risk company uses interest rate swaps part interest rate risk management strategy interest rate swaps used principally fixedtofloating rate swaps designated fairvalue hedges sfas accounting derivative instruments hedging activities requires interest rate swaps qualify fairvalue hedge accounting well underlying debt reported fair value swaps underlying debt revalued resulting million increase noncurrent assets longterm debt december swaps generally held maturity intended create appropriate balance fixed floating rate debt company company estimates increase decrease basis points shortterm longterm interest rates would decrease increase fair value companys interest rate swaps million excluding effects counterparty credit risk additional information see note fair value measurements note cash cash equivalents marketable securities note shortterm borrowings longterm debt note financial instruments bristolmyers squibb consolidated statements earnings dollars shares millions except per share data year ended december earnings net sales costs products sold marketing selling administrative advertising product promotion research development acquired inprocess research development provision restructuring net litigation expense net gain sale product lines businesses equity net income affiliates gain sale imclone shares expense net total expenses net earnings continuing operations income taxes minority interest provision income taxes minority interest net taxes net earnings continuing operations discontinued operations earnings net taxes gain disposal net taxes net earnings earnings per common share basic net earnings continuing operations discontinued operations earnings net taxes gain disposal net taxes net earnings per common share diluted net earnings continuing operations discontinued operations earnings net taxes gain disposal net taxes net earnings per common share average common shares outstanding basic diluted dividends declared per common share accompanying notes integral part financial statements annual report consolidated statements comprehensive income retained earnings dollars millions year ended december comprehensive income net earnings comprehensive incomeloss foreign currency translation foreign currency translation reclassified net earnings due business divestitures foreign currency translation hedge net investment derivatives qualifying cash flow hedges net tax derivatives qualifying cash flow hedges reclassified net earnings net tax minimum pension liability adjustment net tax pension postretirement benefits net tax pension postretirement benefits reclassified net earnings net tax available sale securities net tax available sale securities reclassified net earnings net tax total comprehensive lossincome comprehensive income retained earnings retained earnings january cumulative effect adoption fin net earnings cash dividends declared retained earnings december accompanying notes integral part financial statements bristolmyers squibb consolidated balance sheets dollars millions except share per share data december assets current assets cash cash equivalents marketable securities receivables net allowances inventories net deferred income taxes net valuation allowances prepaid expenses assets held sale total current assets property plant equipment net goodwill intangible assets net deferred income taxes net valuation allowances assets total assets liabilities current liabilities shortterm borrowings accounts payable accrued expenses deferred income accrued rebates returns us foreign income taxes payable dividends payable accrued litigation liabilities liabilities related assets held sale total current liabilities pension postretirement postemployment liabilities deferred income us foreign income taxes payable liabilities longterm debt total liabilities commitments contingencies note stockholders equity preferred stock convertible series par value per share authorized million shares issued outstanding liquidation value per share common stock par value per share authorized billion shares billion issued outstanding capital excess par value stock restricted stock accumulated comprehensive loss retained earnings less cost treasury stock million common shares total stockholders equity total liabilities stockholders equity accompanying notes integral part financial statements annual report consolidated statements cash flows dollars millions year ended december cash flows operating activities net earnings adjustments reconcile net earnings net cash provided operating activities depreciation amortization deferred income tax expensebenefits stockbased compensation expense acquired inprocess research development impairment charges gain sale product lines businesses gainloss debt buybackrestructuring interest rate swap termination loss sale property plant equipment gain sale imclone investments changes operating assets liabilities receivables inventories deferred income accounts payable us foreign income taxes receivablepayable changes operating assets liabilities net cash provided operating activities cash flows investing activities proceeds sale marketable securities purchases marketable securities additions property plant equipment capitalized software proceeds sale property plant equipment investment companies proceeds sale product lines businesses proceeds sale leaseback properties milestone payments intangible assets purchase businesses net cash acquired proceeds sale imclone shares net cash provided byused investing activities cash flows financing activities shortterm repaymentsborrowings longterm debt borrowings longterm debt repayments interest rate swap termination issuances common stock stock plans excess tax benefits sharebased payment arrangements dividends paid net cash used financing activities effect exchange rates cash cash equivalents increasedecrease cash cash equivalents cash cash equivalents beginning period cash cash equivalents end period consolidated statements cash flows include activities discontinued operations accompanying notes integral part financial statements bristolmyers squibb note accounting policies basis consolidation consolidated financial statements prepared conformity united states generally accepted accounting principles include accounts bristolmyers squibb company controlled majorityowned subsidiaries intercompany balances transactions eliminated company entered codevelopment cocommercialization license arrangements parties various therapeutic areas terms including upfront contingent payments arrangements parties determined variable interest entities requirements fin r consolidation variable interest entities primarily due company providing subordinated financial support result company consolidate financial results parties reclassifications certain prior year amounts reclassified conform current year presentation among changes company reclassified certain receivables sale products alliance partners new presentation also changed previously reported line items within consolidated statements cash flows however new presentation change net cash provided operating activities see note receivables net use estimates preparation financial statements requires use estimates assumptions based complex judgments considered reasonable affect reported amounts assets liabilities disclosure contingent assets contingent liabilities date financial statements reported amounts revenues expenses reporting period significant assumptions employed estimates used determining values intangible assets restructuring charges accruals sales rebate return accruals legal contingencies tax assets tax liabilities stockbased compensation expense retirement postretirement benefits including actuarial assumptions financial instruments observable market quotes well estimates used applying revenue recognition policy actual results may may differ estimated results revenue recognition company recognizes revenue title substantially risks rewards ownership transferred customer generally revenue recognized time shipment however case certain sales made nutritionals business certain nonus businesses within pharmaceuticals segment revenue recognized date receipt purchaser see note alliances collaborations discussion revenue recognition related alliances revenues reduced time recognition reflect expected returns estimated based historical experience business trends additionally provisions made time revenue recognition discounts rebates estimated sales allowances based historical experience updated changes facts circumstances appropriate provisions recorded reduction revenue case new products product introduction extension existing line product company determines products similar therapeutic category company determines new product dissimilar characteristics existing products company reliably estimate expected returns new product company defers recognition revenue right return longer exists company developed sufficient historical experience estimate sales returns annual report sales rebate return accruals sales rebate return accruals established period related revenue recognized resulting reduction sales establishment liability included accrued rebates returns accrual recorded based estimate proportion recorded revenue result rebate return prime vendor chargeback accruals cash discounts established similar manner recorded reduction accounts receivable accrued liabilities reductions trade receivables follows december dollars millions medicaid rebates women infants children rebates sales returns managed health care rebates contract discounts prime vendor chargebacks cash discounts adjustments income taxes provision income taxes determined using asset liability approach accounting income taxes approach deferred taxes represent future tax consequences expected occur reported amounts assets liabilities recovered paid provision income taxes represents income taxes paid payable current year plus change deferred taxes year deferred taxes result differences financial tax bases companys assets liabilities adjusted changes tax rates tax laws changes enacted valuation allowances recorded reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecast future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made cash cash equivalents cash cash equivalents consist us treasury backed securities bank deposits time deposits money market funds cash equivalents primarily highly liquid investments original maturities three months less time purchase recorded cost approximates fair value company maintains cash cash equivalent balances us dollars foreign currencies subject currency rate risk marketable securities company determined appropriate classification marketable securities available sale time purchase companys investments marketable securities reported fair value december fair value determined based observable market quotes valuation models using assessments counterparty credit worthiness credit default risk underlying security overall capital market liquidity declines fair value considered temporary charged earnings considered temporary reported component accumulated comprehensive income stockholders equity company uses average cost method determining cost basis computing realized gains losses sale available sale securities realized gains losses included expense net inventory valuation inventories generally stated average cost excess market capital assets depreciation expenditures additions renewals improvements capitalized cost depreciation generally computed straightline method based estimated useful lives related assets estimated useful lives major classes depreciable assets years buildings years machinery equipment fixtures company periodically evaluates whether current events circumstances indicate carrying value depreciable assets may recoverable bristolmyers squibb impairment longlived assets company periodically evaluates whether current facts circumstances indicate carrying value depreciable assets held used may recoverable circumstances determined exist estimate undiscounted future cash flows produced longlived asset appropriate grouping assets compared carrying value determine whether impairment exists asset determined impaired loss measured based difference assets fair value carrying value estimate assets fair value based quoted market prices active markets available quoted market prices available estimate fair value based various valuation techniques including discounted value estimated future cash flows company reports asset disposed lower carrying value estimated net realizable value capitalized software certain costs obtain internal use software significant systems projects capitalized amortized estimated useful life software ranges three years costs obtain software projects significant expensed incurred capitalized software net accumulated amortization included intangible assets net million million december respectively amortization expense million million million investments company accounts lessowned companies ability exercise significant influence using equity method accounting otherwise cost method used companys share net income losses equity investments included equity net income affiliates consolidated statements earnings losses recognized expense net decline market value deemed temporary company reviews equity investments impairment based determination whether decline market value investment companys carrying value temporary making determination company considers factors evaluated determining whether loss value recognized including companys ability hold investment market price market price fluctuations investments publicly traded shares inability investee sustain earnings capacity would justify carrying amount investment acquisitions companys consolidated financial statements results operations reflect acquired business completion acquisition restated acquired businesses accounted using purchase method accounting requires assets acquired liabilities assumed recorded date acquisition respective fair values excess purchase price estimated fair values net assets acquired recorded goodwill amounts allocated acquired inprocess research development expensed date acquisition goodwill recognized acquired net assets constitute business goodwill intangible assets goodwill tested impairment annually using twostep process first step identify potential impairment second step measures amount impairment loss goodwill deemed impaired carrying amount reporting units goodwill exceeds estimated fair value pharmaceutical segment includes four separate reporting units based geography nutritionals segment consists one reporting unit company completed annual goodwill impairment assessment first quarter monitored potential impairment remaining quarters none indicated impairment goodwill intangible assets net consisting patentstrademarks licenses technology capitalized software amortized straight line basis useful lives ranging two years intangible assets deemed impaired net carrying value exceeds estimated fair value restructuring company recognized restructuring charges connection activities streamline operations rationalize manufacturing facilities result company made estimates judgments regarding future plans including future termination benefits exit costs incurred restructuring actions take place actual results may vary estimates annual report product liability accruals product liability including associated legal costs recorded undiscounted basis probable liability incurred amount liability reasonably estimated based existing information accruals adjusted periodically assessment efforts progress additional information becomes available receivables related insurance third party recoveries product liabilities recorded undiscounted basis probable recovery realized classified reduction litigation expense net consolidated statements earnings contingencies normal course business company subject loss contingencies legal proceedings claims arising business cover wide range matters including among others government investigations shareholder lawsuits product environmental liability company records accruals loss contingencies probable liability incurred amount loss reasonably estimated company recognize gain contingencies realized discussion contingencies see note legal proceedings contingencies derivative financial instruments derivative financial instruments used company principally management interest rate foreign currency exposures company hold issue derivative financial instruments speculative purposes company records derivative instruments balance sheet fair value changes derivatives fair value recognized earnings unless specific hedge criteria met derivative designated fair value hedge changes fair value derivative hedged item attributable hedged risk recognized consolidated statements earnings derivative designated cash flow hedge effective portions changes fair value derivative recorded oci subsequently recognized consolidated statements earnings hedged item affects earnings cash flows classified consistent underlying hedged item purchased foreign currency options entire change fair value included measurement hedge effectiveness cash flow hedges ineffective portions changes fair value cash flow hedges recognized charge credit earnings company designates assigns derivatives hedges forecasted transactions specific assets specific liabilities hedged assets liabilities sold extinguished forecasted transactions hedged longer expected occur company immediately recognizes gain loss designated hedging financial instruments consolidated statements earnings shipping handling costs company typically charge customers shipping handling costs therefore shipping handling costs included marketing selling administrative expenses million million million advertising costs advertising costs expensed incurred advertising expense million million million research development research development costs expensed incurred company time time enter strategic alliances third parties give company rights develop manufacture market andor sell pharmaceutical products rights owned third parties result alliances company may obligated make payments alliance partners connection research development contingent upon achievement certain predetermined criteria milestones achieved prior regulatory approval product payments expensed research development milestone payments made connection regulatory approvals including nonus regulatory approvals additional indications capitalized amortized cost products sold remaining useful life asset capitalized milestone payments tested recoverability periodically whenever events changes circumstances indicate carrying amounts may recoverable company records research development net reimbursements connection collaboration agreements bristolmyers squibb acquired inprocess research development fair value inprocess research development acquired business combination determined based present value research projects projected cash flows income approach utilized consistent guidance practice aid issued american institute certified public accountants assets acquired business combinations used research development activities focus software electronic devices pharmaceutical industries future cash flows predominately based net income forecast project consistent historical pricing margins expense levels similar products revenues estimated based relevant market size growth factors expected industry trends individual project life cycles life research projects underlying patent determining fair value research project expected revenues first adjusted technical risk completion resulting cash flows discounted rate approximating companys weightedaverage cost capital acquired inprocess research development expensed incurred underlying product received regulatory approval future alternative use addition costs nonrefundable related acquisition licensing products yet received regulatory approval marketed alternative future use charged earnings incurred earnings per share basic earnings per common share computed using weightedaverage number shares outstanding year diluted earnings per common share computed using weightedaverage number shares outstanding year plus incremental shares outstanding assuming exercise dilutive stock options restricted stock convertible instruments foreign currency translation statements earnings company 's foreign subsidiaries translated us dollars using average exchange rates net assets companys foreign subsidiaries translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recorded foreign currency translation adjustment account included accumulated oci recently issued accounting standards effective january company adopted emerging issues task force eitf issue accounting nonrefundable advance payments goods services received use future research development activities nonrefundable advance payments goods services used rendered future research development activities deferred capitalized amounts recognized expense related goods delivered services performed goods services longer expected provided companys adoption eitf material effect companys consolidated financial statements effective january company adopted statement financial accounting sfas fair value option financial assets financial liabilities including amendment sfas accounting certain investments debt equity securities permits entity measure certain financial assets financial liabilities fair value objective sfas improve financial reporting allowing entities mitigate volatility reported earnings caused measurement related assets liabilities using different attributes without apply complex hedge accounting provisions sfas entities elect fair value option instrument report unrealized gains losses earnings subsequent reporting date fair value option election irrevocable unless new election date occurs sfas establishes presentation disclosure requirements help financial statement users understand effect entitys election earnings eliminate disclosure requirements accounting standards assets liabilities measured fair value must displayed face balance sheet company chose elect fair value option financial assets liabilities existing january elect fair value option financial assets liabilities assets liabilities previously carried fair value therefore adoption sfas impact companys consolidated financial statements effective january company adopted provisions sfas fair value measurements financial assets liabilities assets liabilities carried fair value pronouncement defines fair value establishes framework measuring fair value expands disclosures fair value measurements implementation sfas nonfinancial assets liabilities effective january companys adoption sfas relating financial assets liabilities material effect companys consolidated financial statements adoption sfas respect non financial assets liabilities future expected material impact companys consolidated financial statements annual report march fasb issued sfas disclosures derivative instruments hedging activities amendment sfas accounting derivative instruments hedging activities sfas requires objectives using derivative instruments disclosed terms underlying risk accounting designation fair value derivative instruments gains losses need presented tabular format order present complete picture effects using derivative instruments sfas effective financial statements issued fiscal years beginning november company provided required disclosures december consolidated financial statements december meeting fasb ratified consensus reached eitf issue accounting collaborative arrangements related development commercialization intellectual property eitf concluded collaborative arrangement one participants actively involved exposed significant risks rewards depend ultimate commercial success endeavor revenues costs incurred third parties connection collaborative arrangements would presented gross net based criteria eitf reporting revenue gross principal versus net agent accounting literature payments collaborators would evaluated presented based nature arrangement terms nature entitys business whether payments within scope accounting literature nature purpose collaborative arrangements disclosed along accounting policies classification amounts significant financial statement amounts related arrangements activities arrangement conducted separate legal entity accounted accounting literature however required disclosure eitf applies entire collaborative agreement eitf effective fiscal years beginning december applied retrospectively periods presented collaborative arrangements existing effective date accounting pronouncement material effect companys consolidated financial statements december fasb issued sfas noncontrolling interests consolidated financial statementsan amendment arb sfas establishes accounting reporting standards require ownership interests subsidiaries held parties parent clearly identified labeled presented consolidated balance sheets within equity separate parents equity fasb also requires amount consolidated net income attributable parent noncontrolling interest clearly identified presented face consolidated statements income changes parents ownership interest parent retains controlling financial interest subsidiary must accounted consistently subsidiary deconsolidated retained noncontrolling equity investment former subsidiary must initially measured fair value fasb also requires entities provide sufficient disclosures clearly identify distinguish interests parent interests noncontrolling owners fasb effective company january also change companys consolidated financial statements presentation december fasb issued sfas r business combinations replaces sfas business combinations requires recognition assets acquired liabilities assumed noncontrolling interest acquiree acquisition date measured fair values date business combination achieved stages fasb requires recognition identifiable assets liabilities well noncontrolling interest acquiree full amounts fair values fasb also requires fair value acquired inprocess research development recorded indefinite lived intangibles contingent consideration recorded acquisition date restructuring acquisitionrelated deal costs expensed incurred addition excess fair value net assets acquired purchase price subsequent changes estimated contingencies recorded earnings fasb applies companys business combinations acquisition date january july fasb issued fasb interpretation fin accounting uncertainty income taxes interpretation fasb statement case company effective january fin clarifies accounting uncertainty income taxes recognized enterprises financial statements accordance sfas accounting income taxes fin requires tax positions evaluated using recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return differences tax positions taken tax return amounts recognized financial statements recorded adjustments income taxes payable receivable adjustments deferred taxes fin also requires expanded disclosure end reporting period including tabular reconciliation unrecognized tax benefits company adopted fin january result adoption accounting pronouncement company recognized million previously unrecognized tax benefits accounted increase opening balance retained earnings may fasb issued fasb staff position fsp fin definition settlement fasb interpretation effective retroactively january fsp fin provides guidance determine whether tax position effectively settled purpose recognizing previously unrecognized tax benefits adoption fsp fin effect companys consolidated financial statements bristolmyers squibb note alliances collaborations sanofi company agreements sanofiaventis codevelopment cocommercialization avaproavalide angiotensin ii receptor antagonist indicated treatment hypertension diabetic nephropathy plavix platelet aggregation inhibitor worldwide alliance operates framework two geographic territories one americas principally us canada puerto rico latin american countries australia europe asia accordingly two territory partnerships formed manage central expenses marketing research development royalties supply finished product individual countries general country level agreements either copromote whereby partnership formed parties sell brand comarket whereby parties operate sell brands independently place agreements expire later respect plavix respect avaproavalide americas australia europe asia ii expiration patents exclusivity rights applicable territory company acts operating partner territory covering americas australia owns majority controlling interest territory sanofis ownership interest territory company consolidates country partnership results territory records sanofis share results minority interest net taxes million million million company recorded net sales territory comarketing countries outside territory germany italy spain greece million million million cash flows operating activities partnerships territory covering americas australia recorded operating activities within companys consolidated statements cash flows distributions partnership profits sanofi sanofis funding ongoing partnership operations occur routine basis also recorded within operating activities companys consolidated statements cash flows sanofi acts operating partner territory covering europe asia owns majority financial controlling interest within territory companys ownership interest partnerships within territory company accounts investment partnership entities territory equity method records share results equity net income affiliates consolidated statements earnings companys share income partnership entities taxes million million million company routinely receives distributions profits provides funding ongoing operations partnerships territory covering europe asia transactions recorded operating activities within companys consolidated statements cash flows company sanofi alliance copromotion irbesartan company recognized income million million million related amortization deferred income associated sanofis million payment company acquisition interest irbesartan license us upon formation alliance unrecognized portion deferred income amounted million million december respectively continue amortize expected expiration license following summarized financial information companys interests partnerships sanofi territory covering europe asia year ended december dollars millions net sales gross profit net income current assets current liabilities otsuka company worldwide commercialization agreement otsuka pharmaceutical co ltd codevelop copromote otsuka abilify treatment schizophrenia bipolar mania disorder major depressive disorder except japan china taiwan north korea south korea philippines thailand indonesia pakistan egypt terms agreement company purchases product otsuka performs finish manufacturing sale company otsuka thirdparty customers product currently copromoted otsuka us united kingdom germany france spain us germany spain product invoiced thirdparty customers company behalf otsuka company records alliance revenue contractual share thirdparty net sales records expenses related product company recognizes alliance revenue abilify shipped risks rewards ownership transferred thirdparty customers uk france annual report italy company presently exclusive distributor product company records net sales related cost products sold expenses company also exclusive right sell abilify countries europe americas number countries asia countries company records net sales related cost products sold agreement expires november us entire european union eu agreement expires june country company exclusive right sell abilify agreement expires later th anniversary first commercial sale country expiration applicable patent country company recorded net sales abilify million million million total milestone payments made otsuka agreement december million million expensed acquired inprocess research development remaining million capitalized intangible assets net amortized cost products sold remaining life agreement us company amortized cost products sold million unamortized capitalized payment balance million million december respectively imclone company commercialization agreement expiring september imclone codevelopment copromotion erbitux us well codevelopment copromotion rights canada japan extent product commercialized countries erbitux indicated use treatment patients metastatic colorectal cancer use treatment squamous cell carcinoma head neck agreement covering north america imclone receives distribution fee based flat rate net sales north america october company imclone amended codevelopment agreement merck kgaa provide cocommercialization erbitux japan expires imclone ability terminate agreement determines commercially unreasonable imclone continue erbitux received marketing approval japan july use erbitux treating patients advanced recurrent colorectal cancer company recorded net sales erbitux million million million company amortized cost products sold million million million previously capitalized milestone payments accounted license acquisition unamortized portion approval payments recorded intangible assets net million million december respectively continue amortize remaining term agreement upon initial execution commercialization agreement company acquired ownership interest imclone approximated time transaction noted accounting investment equity method company recorded equity loss income affiliates adjusted revenue recognized imclone preapproved milestone payments made company prior million equity net income affiliates million million november eli lilly company acquired imclone result company sold shares imclone billion recognized pretax gain million company continue marketing rights erbitux believes rights imclones investigational compound imcf gilead company gilead sciences inc joint venture develop commercialize atripla oncedaily single tablet threedrug regimen combining companys sustiva gileads truvada emtricitabine tenofovir disoproxil fumarate us canada europe atripla approved fda july health canada october european commission december commercialization countries eu well norway iceland gilead records atripla revenues us canada countries europe consolidates results joint venture operating results company records revenue bulk efavirenz component atripla upon sales product joint venture thirdparty customers company 's net sales efavirenz component determined applying percentage atripla revenue approximates revenue sustiva brand limited number eu countries company records revenue atripla company agreed purchase product gilead distribute thirdparty customers company recorded revenues million million million related atripla sales company accounts participation us joint venture equity method accounting records share joint venture results equity net income affiliates consolidated statements earnings company recorded equity loss us joint venture gilead million million bristolmyers squibb astrazeneca january company entered two worldwide except japan codevelopment cocommercialization agreements astrazeneca plc one codevelopment cocommercialization saxagliptin dppiv inhibitor saxagliptin agreement one codevelopment cocommercialization dapagliflozin sodiumglucose contransporter sglt inhibitor sglt agreement compounds studied treatment diabetes discovered company terms agreements company received astrazeneca upfront payment million january october company received astrazeneca milestone payment million june filing new drug application food drug administration onglyza companies proposed name onglyza approved fda european medicines evaluation agency serve trade name saxagliptin upfront milestone payments deferred recognized useful life products income company amortized income million upfront payments million unamortized portion upfront milestone payments million december million december additional milestone payments expected received company upon successful achievement various development regulatory events well salesrelated milestones saxagliptin agreement company could receive million development regulatory milestones met additional million salesbased milestones met sglt agreement company could receive million development regulatory milestones met additional million salesbased milestones met agreement company astrazeneca also share development commercialization costs majority development costs initial development plans paid astrazeneca additional development costs generally shared equally company records development costs related saxagliptin dapagliflozin net astrazenecas share research development expenses agreement two companies jointly develop clinical marketing strategy share commercialization expenses profitslosses equally global basis excluding japan company manufacture products pfizer april company pfizer inc entered worldwide codevelopment cocommercialization agreement apixaban anticoagulant discovered company studied prevention treatment broad range venous arterial thrombotic conditions accordance terms agreement pfizer made upfront payment million company may deferred recognized life agreement income december company pfizer agreed include japan worldwide agreement connection japan agreement pfizer made additional upfront payment million december deferred recognized useful life product income company amortized income million two upfront payments million unamortized portion upfront payments million december million december pfizer fund development costs effective january going forward company fund company records apixaban development costs net pfizers share research development expenses company may also receive additional payments million pfizer based development regulatory milestones companies jointly develop clinical marketing strategy share commercialization expenses profitslosses equally global basis manufacture product arrangement exelixis december company exelixis entered global codevelopment cocommercialization arrangement xl oral anticancer compound license xl utility ras raf mutant tumors development exelixis terms arrangement company agreed pay exelixis million upon execution agreement additional million company expensed research development million upon execution agreement exelixis fund first million development xl exelixis elects continue sharing development costs elects copromote us exelixis fund future global development costs excluding japan share us profitslosses equally failing elections exelixis receives milestones royalties company fund development costs japan addition doubledigit royalties nonus sales company could pay million development regulatory milestones met additional million salesbased milestones met addition company exelixis history collaborations identify develop promote oncology targets december company exelixis entered oncology collaboration license agreement exelixis pursuing development three small molecule inds codevelopment copromotion terms agreement company paid exelixis million upfront fees company paid exelixis million ind acceptance milestones exelixis elects fund development costs copromote us parties equally share development costs profits exelixis opts codevelopment copromotion agreement bms take full development us commercial rights successful pay exelixis development regulatory milestones million additional million salesbased milestones well doubledigit royalties annual report note restructuring december july company announced productivity transformation initiatives designed fundamentally change way runs business meet challenges changing business environment take advantage diverse opportunities marketplace company transformed nextgeneration biopharma company create total billion annual productivity cost savings cost avoidance connection pti company aims achieve culture continuous improvement enhance efficiency effectiveness competitiveness substantially improve cost base charges associated previously announced pti estimated aggregate range billion billion includes million costs already incurred incurred costs net million gains related sale mature product lines businesses exact timing recognition pti charges predicted certainty affected existence triggering events expense recognition among factors also included charges net termination benefits million million exit costs million million net restructuring charges include termination benefits workforce reduction approximately manufacturing selling administrative research development personnel across geographic regions following table presents details expenses incurred segment corporateother connection restructuring activities termination termination exit termination exit dollars millions benefits exit costs total benefits costs total benefits costs total pharmaceuticals nutritionals corporateother subtotal changes estimates provision restructuring net following table represents reconciliation restructuring liabilities spending liabilities exit termination costs dollars millions liability liability total liability january charges spending changes estimates liability december charges spending changes estimates liability december charges spending change estimates convatec divestiture liability december addition termination charges company recognized accelerated depreciation fixed asset impairment charges shutdown costs million million million charges included cost products sold primarily relate rationalization companys manufacturing network pharmaceuticals segment assets continue depreciated facility closures complete remaining costs pti primarily attributed process standardization activities across company recognized incurred bristolmyers squibb note acquisitions divestitures june company completed acquisition kosan biosciences inc cancer therapeutics company library novel compounds including hsp inhibitors cancer microtubule stabilizers may additional potential neurodegenerative diseases net purchase price approximately million transaction accounted purchase method accounting purchase price preliminarily allocated acquiredinprocess research development million net assets million goodwill million october company completed acquisition adnexus therapeutics inc developer new therapeutic class biologics called adnectins net purchase price million addition event certain future development regulatory milestones achieved company obligated terms agreement pay former stockholders adnexus additional million transaction accounted purchase method accounting purchase price allocated acquiredinprocess research development million identifiable intangible assets million existing process technology used future discovery net assets million goodwill million reflecting additional deferred tax assets million results operations two acquisitions included accompanying consolidated financial statements dates acquisition pro forma supplemental financial information included impact business combinations material december company completed sale mature brand business located egypt million cash glaxosmithkline result transaction company recognized pretax gain million million net tax fourth quarter august company completed divestiture convatec business january company completed divestiture bristolmyers squibb medical imaging see note discontinued operations assets held sale discussions divestitures july company completed sale bufferin excedrin brands japan asia excluding china taiwan certain oceanic countries lion corporation japan million cash result transaction company recognized pretax gain million million net tax third quarter january company completed sale inventory trademark patent intellectual property rights us related dovonex treatment psoriasis warner chilcott company inc million cash addition company received royalty based net sales dovonex end result transaction company recognized pretax gain million million net tax first quarter note mead johnson nutrition company initial public offering february mead johnson nutrition company completed initial public offering ipo sold million shares class common stock per share net proceeds received approximately million allocated minority interest net taxes capital excess par value stock within companys stockholders equity accordance sfas noncontrolling interests consolidated financial statements amendment arb upon completion ipo company held million shares mead johnson class common stock million shares mead johnson class b common stock rights holders shares class common stock class b common stock identical except regard voting conversion share class common stock entitled one vote per share share class b common stock entitled ten votes per share convertible time election holder one share class common stock class b common stock automatically convert shares class common stock certain circumstances upon completion ipo company holds interest mead johnson mead johnson continue consolidated financial reporting purposes company entered various agreements relating separation mead johnson including separation agreement transitional services agreement tax matters agreement registration rights agreement employee matters agreement february mead johnson entered three year syndicated revolving credit facility agreement credit facility unsecured provides borrowings letters credit million annual report note discontinued operations assets held sale august company completed divestiture convatec business cidron healthcare limited affiliate nordic capital fund vii avista capital partners lp avista gross purchase price approximately billion resulting pretax gain billion billion net tax included discontinued operations gross purchase price includes estimated postclosing purchase price adjustment based companys estimate closing working capital convatec business therefore purchase price transaction gain subject future adjustment based actual closing working capital convatec business pursuant terms stock asset purchase agreement dated may addition company recorded discontinued operations curtailment loss million special termination benefits million associated remeasurement us japan pension plans obligations assets triggered decision sell convatec business results convatec business previously reported separate operating segment included earnings discontinued operations net taxes periods presented january company completed divestiture medical imaging avista gross purchase price approximately million excluding post closing adjustments resulting pretax gain million aftertax loss million included discontinued operations results medical imaging business previously included former health care operating segment included earnings discontinued operations net taxes periods presented net assets associated medical imaging business totaling approximately million reclassified assets liabilities held sale december period time company continue generate cash flows report income statement activity expense net associated convatec medical imaging businesses activities give rise cash flows income statement activities transitional nature generally result agreements intended facilitate orderly transfer business operations agreements include among others services accounting customer service distribution manufacturing activities convatec medical imaging businesses expected material companys results operations cash flows convatec agreements extend periods generally less months majority ranging six months transaction close date subject certain cases limited extensions medical imaging agreements extend periods generally less months majority ranging three six months transaction close date subject certain cases closing extensions transitional service fees net identifiable direct costs recognized expense net amounted million year ended december following summarized financial information related convatec medical imaging businesses segregated continuing operations reported discontinued operations date disposition reflect costs certain services provided convatec medical imaging company costs allocated company convatec medical imaging services included without limitation legal counsel insurance external audit fees payroll processing certain human resource services information technology systems support year ended december convatec medical imaging dollars millions net sales earnings incomes taxes curtailment losses special termination benefits provision income taxes earnings net taxes gain disposal provision income taxes gainloss disposal net taxes bristolmyers squibb consolidated statements cash flows includes convatec medical imaging businesses date disposition company uses centralized approach cash management financing operations accordingly debt allocated businesses following table includes medical imaging assets liabilities segregated classified assets held sale liabilities related assets held sale appropriate consolidated balance sheets december amounts presented adjusted exclude cash intercompany receivables payables business held sale company excluded divestiture addition goodwill december million excluded following summary net assets held sale considered determining pretax gain sale first quarter assets generating operating results cash flows included consolidated balance sheet assets held sale december dollars millions december medical imaging assets receivables net allowances inventories net assets property plant equipment net intangible assets net total assets held sale liabilities accounts payable accrued liabilities total liabilities related assets held sale net assets held sale annual report note earnings per share numerator basic earnings per share net earnings available common stockholders numerator diluted earnings per share net earnings available common stockholders interest expense added back assumed conversion convertible debt common stock denominator basic earnings per share weightedaverage number common stock outstanding period denominator diluted earnings per share weightedaverage shares outstanding adjusted effect dilutive stock options restricted shares assumed conversion convertible debt common stock computations basic diluted earnings per common share follows year ended december dollars millions except per share data basic net earnings continuing operations discontinued operations earnings net taxes gain disposal net taxes net earnings basic earnings per share average common shares outstanding basic net earnings continuing operations discontinued operations earnings net taxes gain disposal net taxes net earnings per common share diluted net earnings continuing operations interest expense conversion convertible debt net taxes net earnings continuing operations used diluted earnings per common share calculation discontinued operations earnings net taxes gain disposal net taxes net earnings diluted earnings per share average common shares outstanding basic conversion convertible debt incremental shares outstanding assuming exercisevesting dilutive stock optionsrestricted stock average common shares outstanding diluted net earnings continuing operations discontinued operations earnings net taxes gain disposal net taxes net earnings per common share weightedaverage shares issuable upon exercise stock options million million million included diluted earnings per share calculation antidilutive addition million shares assumed conversion convertible debt included diluted earnings per share calculation antidilutive bristolmyers squibb note expense net components expense net follows year ended december dollars millions interest expense interest income ars impairment charge gainloss debt buyback termination interest rate swap agreements foreign exchange transaction gainslosses net expense net interest expense includes million net interest rate swap gains net interest rate swap losses million million see note financial instruments additional discussion terminated swap contracts interest income relates primarily interest earned cash cash equivalents investments marketable securities detail auction rate securities impairment see note cash cash equivalents marketable securities net includes income thirdparty contract manufacturing certain royalty income expense gains losses sale property plant equipment gains losses sale marketable securities including million loss sale ars insurance recoveries certain litigation chargesrecoveries convatec medical imaging net transitional service fees amortization certain upfront payments related companys alliances see note alliances collaborations note income taxes components earningsloss continuing operations income taxes minority interest follows year ended december dollars millions us nonus amounts categorized based location taxing authorities provisionbenefit income taxes attributable continuing operations consisted year ended december dollars millions current us nonus deferred us nonus annual report effective tax rate companys provision income taxes different amount computed applying statutory us federal income tax rate earnings continuing operations income taxes minority interest result following earnings income taxes minority interest dollars millions earnings continuing operations income taxes minority interest us statutory rate foreign tax effect operations ireland puerto rico switzerland state local taxes net valuation allowance us federal foreign contingent tax matters acquired inprocess research development expense us federal research development tax credit us federal foreign valuation allowance impairment financial instruments foreign increase effective tax rate primarily due higher pretax income us including gain sale imclone earnings mix high tax jurisdictions partially offsetting factors lower nondeductible charges acquired inprocess research development expenses lower ars impairment charges little tax benefit tax rate favorably impacted benefit million tax related final settlement audit internal revenue service tax rate unfavorably impacted impairment companys investment certain ars little tax benefit nondeductible writeoff acquired inprocess research development expenses related acquisition adnexus partially offset tax benefit million first quarter due favorable resolution certain tax matters internal revenue service related deductibility litigation settlement expenses us foreign tax credits claimed effective tax rate unfavorably impacted elimination tax benefits section internal revenue code treatment provisions portion certain litigation reserves nondeductible partially offset favorable us tax legislation enacted related tax treatment certain intercompany transactions amongst companys foreign subsidiaries implementation tax planning strategies related utilization certain charitable contributions bristolmyers squibb deferred taxes valuation allowance components current noncurrent deferred income tax assetsliabilities follows december dollars millions acquired inprocess research development intercompany profit inventory items us federal foreign tax credit carryforwards deferred income us federal research development tax credit carryforwards us federal charitable contribution carryforwards state net operating loss carryforwards foreign net operating loss carryforwards foreign deferred tax assets pension postretirement benefits depreciation sharebased compensation repatriation foreign earnings legal settlements tax deductible goodwill milestone payments license fees net valuation allowance deferred tax assets net recognized deferred income taxes current deferred income taxes noncurrent us foreign income taxes payable liabilities noncurrent total company established valuation allowance deferred tax assets company determined likely deferred tax assets realized december valuation allowance million established following items million state deferred tax assets million foreign net operating loss tax credit carryforwards million state net operating loss tax credit carryforwards million related impaired financial instruments million us federal state deferred tax assets related adnexus kosan acquisitions offset goodwill company recognized significant deferred tax assets december related us federal foreign tax credit carryforwards million us federal research development tax credit carryforwards million us federal charitable contribution carryforwards fully utilized due gains related convatec medical imaging divestitures foreign tax credit research development tax credit carryforwards expire varying amounts beginning foreign tax credit research development tax credit carryforwards reduced due derecognition fin convatec medical imaging divestitures resulted significant reduction foreign tax credit research development tax credit carryforwards realization foreign tax credit research development tax credit carryforwards dependent generating sufficient domesticsourced taxable income prior expiration although realization assured management believes likely deferred tax assets realized income taxes paid year million million million discussed tax rate favorably impacted benefit million tax related final settlement audit internal revenue service final settlement related joint committee congress approval foreign tax credit carryback claim company received million cash refund including interest current tax benefit realized upon exercise stock options credited capital excess par value stock million million annual report december company approximately billion undistributed earnings foreign subsidiaries taxes provided company invested expects invest undistributed earnings permanently offshore future earnings repatriated us company determines earnings remitted foreseeable future additional tax provisions would required due complexities tax laws assumptions would made practicable estimate amounts income taxes would provided company conducts business various countries throughout world subject tax numerous jurisdictions result business activities company files significant number tax returns subject examination various federal state local tax authorities tax examinations often complex tax authorities may disagree treatment items reported company may require several years resolve company establishes liabilities possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known effect changes estimates related contingent tax liabilities included effective tax rate reconciliation company adopted provisions fin january resulting recognition million previously unrecognized tax benefits accounted increase opening balance retained earnings fin requires expanded disclosure end annual reporting period including tabular reconciliation unrecognized tax benefits certain information regarding interest penalty amounts reflected part companys uncertain tax positions tabular reconciliation companys changes uncertain tax positions january december january december follows unrecognized unrecognized income tax unrecognized income tax benefits including interest federal state benefits deferred penalties net foreign including interest income tax deferred income tax dollars millions tax benefits interest penalties penalties benefits benefits total uncertain tax positions recognized would impact effective tax rate january add tax attributable deferred tax items january balance gross uncertain tax positions january gross additions tax positions related current year gross reductions tax positions related current year gross additions tax positions related prior years gross reductions tax positions related prior years settlements reductions tax positions related lapse statute cumulative translation adjustment balance gross uncertain tax positions december less tax attributable deferred tax items december total uncertain tax positions recognized would impact effective tax rate december total uncertain tax positions recognized would impact effective tax rate january add tax attributable deferred tax items january balance gross uncertain tax positions january gross additions tax positions related current year gross reductions tax positions related current year gross additions tax positions related prior years gross reductions tax positions related prior years settlements reductions tax positions related lapse statute cumulative translation adjustment balance gross uncertain tax positions december less tax attributable deferred tax items december total uncertain tax positions recognized would impact effective tax rate december annual tabular reconciliation required fin requires gross presentation unrecognized tax benefits gross basis reductions deferred tax assets companys total amount unrecognized tax benefits january excluding interest penalties million uncertain tax benefits december recorded companys deferred tax assets extent uncertainty directly related asset otherwise recorded either current noncurrent income taxes payable bristolmyers squibb total amount gross uncertain tax benefits december excluding interest penalties decreased million reduction primarily due favorable resolution uncertain tax positions partially offset additional uncertain tax benefits accrued included gross reductions tax positions related prior years million uncertain tax positions longer included fin table result disposition businesses included balance unrecognized tax benefits million uncertain tax positions january million december ultimate deductibility highly certain uncertainty timing deductibility impact deferred tax accounting interest penalties applicable disallowance shorter deductibility period would affect annual effective tax rate would accelerate payment cash taxing authority utilization tax attributes earlier period amounts unrecognized tax benefits recognized would impact effective tax rate million january million december company classifies interest penalties related unrecognized tax benefits income tax expense amounts reflected separately reconciliation total amount interest penalties related uncertain tax positions recognized consolidated statements earnings net benefit million interest million penalties net benefit interest result million additional accrual million reduction interest net benefit penalties result million additional accrual million reduction penalties total amount interest penalties related uncertain tax positions recognized consolidated balance sheets december million interest million penalties company currently examination number tax authorities including major tax jurisdictions listed table proposed adjustments tax issues transfer pricing certain tax credits deductibility certain expenses company estimates reasonably possible total amount unrecognized tax benefits december decrease range approximately million million next twelve months result settlement certain tax audits settlements involve payment additional taxes adjustment certain deferred taxes andor recognition tax benefits company also anticipates reasonably possible new issues raised tax authorities may require increases balance unrecognized tax benefits however estimate increases reasonably made company believes adequately provided open tax years tax jurisdiction fin company files income tax returns us federal jurisdiction various state foreign jurisdictions exceptions company subject us federal state local nonus income tax examinations tax authorities following summary major tax jurisdictions tax authorities may assert additional taxes company based upon tax years currently audit subsequent years likely audited us canada france germany italy mexico annual report note fair value measurement stated note accounting policies january company adopted methods fair value described sfas value financial assets liabilities defined sfas fair value based price would received sell asset paid transfer liability orderly transaction market participants measurement date order increase consistency comparability fair value measurements sfas establishes fair value hierarchy prioritizes observable unobservable inputs used measure fair value three broad levels described level quoted prices unadjusted active markets accessible measurement date identical assets liabilities fair value hierarchy gives highest priority level inputs level observable prices based inputs quoted active markets corroborated market data level unobservable inputs used little market data available fair value hierarchy gives lowest priority level inputs determining fair value company utilizes valuation techniques maximize use observable inputs minimize use unobservable inputs extent possible well considers counterparty credit risk assessment fair value company chose elect fair value option prescribed sfas financial assets liabilities previously carried fair value therefore material financial assets liabilities carried fair value short long term debt obligations trade accounts receivable payable still reported carrying values financial assets liabilities carried fair value december classified table one three categories described dollars millions level level level total available sale us treasury bills equity securities us treasurybacked securities floating rate securities auction rate securities total available sale assets derivatives interest rate swap derivatives foreign exchange derivatives total derivative assets total assets fair value dollars millions level level level total derivatives foreign exchange derivatives natural gas contracts total derivative liabilities total liabilities fair value companys assets utilize level inputs fair value measurement consist auction rate securities floating rate securities due lack observable market quotes companys ars investment portfolio company utilizes valuation models rely exclusively level inputs including based expected cash flow streams collateral values including assessments counterparty credit quality default risk underlying security discount rates overall capital market liquidity valuation companys ars investment portfolio subject uncertainties difficult predict factors may impact companys valuation include changes credit ratings securities well underlying assets supporting securities rates default underlying assets underlying collateral value discount rates counterparty risk ongoing strength quality market credit liquidity companys determination fair value ars investment portfolio december included indicative prices received external banks internally developed valuations based part indicative bids received underlying assets securities nonobservable evidence fair value although ars continue pay interest according stated terms due continued severity capital markets length time ars mature company believes full recovery longer probable discussion companys december fair value carrying value rollforward ars activity including sales otherthantemporary impairment charge recorded see note cash cash equivalents marketable securities bristolmyers squibb companys frs primarily rated abaa better frs longterm debt securities coupons reset periodically benchmark interest rate underlying assets frs consist primarily consumer loans auto loans collateralized loan obligations monoline securities assetbacked securities corporate bonds loans since latter part general frs market became less liquid active due continuing credit liquidity concerns result availability observable market quotes active market level inputs market quotes similar identical assets liabilities inputs derived principally corroborated observable market data correlation means level inputs company markstomarket frs based indicative pricing indicative price quotes represent individual brokers assessments based similar assets well using valuation techniques analyzing underlying assets frs due current lack active market companys frs general lack transparency underlying assets company also relies qualitative analysis including discussions brokers fund managers default risk underlying security overall capital market liquidity level inputs value frs portfolio discussion companys december fair value carrying value rollforward activity occurred see note cash cash equivalents marketable securities financial assets liabilities utilize level level inputs company utilizes direct indirect observable price quotes including libor euribor yield curves foreign exchange forward prices nymex futures pricing common stock price quotes summary valuation techniques level level financial assets liabilities us treasury bills treasurybacked securities valued quoted market price broker dealer quotations transparent pricing sources reporting date equity securities valued using quoted stock prices new york stock exchange national association securities dealers automated quotation system reporting date interest rate swap derivative assets liabilities valued using libor euribor yield curves less credit valuation adjustments reporting date counterparties contracts financial institutions experienced downgrades valuations may fluctuate considerably periodtoperiod due volatility underlying interest rates driven market conditions duration swap addition credit valuation adjustment significant impact valuation companys interest rate swaps due changes counterparty credit ratings credit default swap spreads foreign exchange derivative assets liabilities valued using quoted forward foreign exchange prices reporting date counterparties contracts financial institutions experienced downgrades valuations may fluctuate considerably periodtoperiod due volatility underlying foreign currencies due shortterm maturities companys foreign exchange derivatives generally months less counterparty credit risk significant natural gas forward contracts valued using nymex futures prices natural gas reporting date counterparties contracts financial institutions experienced downgrades valuations may fluctuate considerably periodtoperiod due volatility underlying natural gas prices due shortterm maturities companys natural gas derivatives months less counterparty credit risk significant increases decreases aggregate fair value financial assets liabilities measured fair value would significant impact companys liquidity financial flexibility approximately fair value net financial assets us treasury bills us treasurybacked securities although company elected fair value option financial assets liabilities existing january transacted future transacted financial asset liability evaluated fair value election prescribed sfas fair valued provisions sfas company elect fair value option billion senior notes issued may annual report note cash cash equivalents marketable securities cash cash equivalents december million primarily consisted us treasurybacked securities cash cash equivalents december million primarily consisted bank deposits time deposits money market funds cash equivalents primarily highly liquid investments original maturities three months less time purchase recorded cost approximates fair value company maintains cash cash equivalent balances us dollars foreign currencies subject currency rate risk marketable securities december primarily consisted us treasury bills us dollardenominated frs companys frs holdings downgraded december ratings primarily aaaaaa ratings ranged aaaaaa abaa december frs longterm debt securities coupons reset periodically benchmark interest rate underlying assets companys frs consist primarily consumer loans auto loans collateralized loan obligations monoline securities assetbacked securities corporate bonds loans company accounts marketable securities accordance sfas accounting certain investments debt equity securities classifies available sale noncurrent frs classified noncurrent assets december following tables summarize companys current noncurrent marketable securities december include us dollardenominated frs ars accounted available sale debt securities december unrealized lossgain accumulated dollars millions cost fair value carrying value oci current available sale floating rate securities us treasury bills total current noncurrent available sale auction rate securities floating rate securities total noncurrent december unrealized lossgain accumulated dollars millions cost fair value carrying value oci current available sale floating rate securities total current noncurrent available sale auction rate securities total noncurrent company recognized pretax otherthantemporary impairment charge million respectively million loss sale certain securities december companys principal value frs amounted million company received million principal par primarily frs matured march temporarily reduced fair value remaining frs million million unrealized loss accumulated oci addition company reclassified million remaining frs maturity dates beyond current assets noncurrent assets due liquidity concerns continued uncertainty capital markets bristolmyers squibb company received million connection sale ars carrying value million resulting loss million addition million otherthantemporary impairment charge recognized including million previously determined temporary december impairment charge required analysis otherthan temporary impairment factors including severity duration decline value future prospects issuer companys ability intent hold security recovery ars sold securities generally backed subprime mortgages collateralized debt obligations structured credit ars remaining december primarily represents interests insurance securitizations lesser extent structured credits following table summarizes activity financial assets fair value measurements estimated utilizing level inputs ars frs noncurrent dollars millions current frs frs ars total carrying value january settlements transfers current noncurrent total losses included earnings included comprehensive income carrying value december discussion fair value financial instruments including ars frs see note fair value measurement contractual maturities carrying value available sale debt securities december follows dollars millions within year years years years total available sale floating rate securities auction rate securities us treasury bills total available sale note receivables net major categories receivables follows december dollars millions trade receivables alliance partner receivables income tax refund claims miscellaneous receivables less allowances receivables net receivables netted deferred income sales product alliance partners recognition revenue result corresponding reclassification made reduced alliance partner receivables deferred income million million december respectively additional information company 's alliance partners see note alliances collaborations aggregate receivables due three pharmaceutical wholesalers us represented total trade receivables december respectively annual report note inventories net major categories inventories follows december dollars millions finished goods work process raw packaging materials inventories net inventories expected remain onhand beyond one year million million december respectively included noncurrent assets note property plant equipment net major categories property plant equipment follows december dollars millions land buildings machinery equipment fixtures construction progress less accumulated depreciation property plant equipment net capitalized interest million million million note goodwill changes carrying amount goodwill segment years ended december follows convatec pharmaceuticals nutritionals medical dollars millions segment segment imaging total balance january acquisition adnexus adjustments balance january sale medical imaging sale convatec sale mature brand business egypt acquisition kosan adnexus purchase price adjustment balance december see note acquisitions divestitures detail bristolmyers squibb note intangible assets net december intangible assets consisted following total intangible patentstrademarks licenses technology capitalized software assets dollars millions gross carrying amount less accumulated amortization intangible assets net change carrying amount intangible assets years ended december follows total intangible assets dollars millions intangible assets net carrying amount january additions acquisition adnexus amortization medical imaging assets held sale sale convatec impairment charges intangible assets net carrying amount december impairment charges relate certain patent product rights acquired dupont results development programs abandoned license terminations amortization expense intangible assets million million million amortization expense intangible assets related convatec medical imaging reflected discontinued operations million million million expected amortization expense related current net carrying amount intangible assets follows years ending december dollars millions later years note accrued expenses major categories accrued expenses follows december dollars millions employee compensation benefits royalties accrued research development restructuring current pension postretirement benefits annual report note shortterm borrowings longterm debt shortterm borrowings million million december respectively september company repaid million principal amount million aggregate principal amount floating rate convertible senior debentures due result partial redemption note holders portion remaining balance million redeemed holders par september fundamental change ownership company occurs part remaining debt callable par time issuer debentures conversion price conversion rate shares subject certain antidilutive adjustments maximum conversion rate shares debentures pay interest quarterly annual rate equal three month libor reset quarterly minus yield never less zero august february company repaid million notes due million yen notes due respectively december company obtained billion five year revolving credit facility syndicate lenders extendable anniversary date consent lenders facility contains customary terms conditions including financial covenant whereby ratio consolidated debt consolidated capital exceed end quarter company compliance covenant since inception new facility borrowings outstanding revolving credit facility december components longterm debt follows december december dollars millions principal value notes due notes due euro notes due euro notes due notes due notes due debentures due debentures due debentures due floating rate convertible senior debentures due industrial revenue bonds due yen notes due variable rate industrial revenue bonds due subtotal adjustments principal value fair value interest rate swaps unamortized proceeds swap terminations unamortized bond discounts discussion companys interest rate swaps refer note financial instruments bristolmyers squibb november december company repurchased approximately million principal amount debt terminated million notional amount interest rate swaps resulting gain million reported expense net table summarizes debt repurchase related activity principal repurchase swap termination earnings dollars millions amount price gain repurchase proceeds impact notes due debentures due debentures due notes due total may company issued million aggregate principal amount notes due billion aggregate principal amount notes due collectively may issued notes registered public offering interest payments made may november year beginning november may issued notes senior unsecured obligations company rank equally right payment companys existing future senior unsecured indebtedness company may redeem may issued notes whole part time redemption price equal greater par value amount calculated based upon sum present values remaining scheduled payments set forth prospectus supplement dated april december company terminated million notional amount fixedtofloating interest rate swap agreements related notes due received proceeds million proceeds recognized interest expense remaining life underlying debt september company terminated million notional amount fixedtofloating interest rate swap agreements related million debentures due received proceeds million proceeds recognized interest expense remaining life underlying debt approximately million pretax recognized years discussion companys swap terminations refer note financial instruments including payments due interest rate swaps cash payments interest million million million cash receipts interest rate swaps million million million excluded cash payments interest companys principal value longterm debt obligations million december million due million due remaining million due later december company provided total million financial guarantees form standby letters credit performance bonds standby letters credit insurance companies support thirdparty liability programs performance bonds issued support range ongoing operating activities including sale company products hospitals foreign ministries health bonds customs duties value added tax guarantees related miscellaneous legal actions significant majority companys outstanding financial guarantees expire within year expected funded note stockholders equity changes common shares treasury stock capital excess par value stock restricted stock follows cost capital excess common shares treasury treasury par value restricted dollars shares millions issued stock stock stock stock balance january employee stock compensation plans balance december employee stock compensation plans balance december employee stock compensation plans balance december share companys preferred stock convertible shares common stock callable companys option reductions number issued shares preferred stock due conversions shares common stock annual report accumulated balances related component oci net taxes follows pension accumulated foreign derivatives minimum currency qualifying cash pension postretirement available comprehensive dollars millions translation flow hedges liability benefits sale securities incomeloss balance january comprehensive incomeloss adjustments adoption sfas balance december comprehensive incomeloss balance december comprehensive incomeloss balance december note employee stock benefit plans employee stock plans may stockholders approved companys stock award incentive plan plan plan replaced stock incentive plan plan expired may plan provides million new shares common stock reserved delivery participants plus shares remaining available new grants plan shares recaptured outstanding awards plan number shares actually delivered participants connection award restrictions lapsed counted number shares reserved shares tendered prior year pay purchase price options number shares previously utilized satisfy withholding tax obligations upon exercise continue available reserved december million million shares common stock respectively reserved issuance pursuant stock plans options conversions preferred stock million million shares available granted active plans december respectively adjusted combination plans companys plan plan executive officers key employees may granted options purchase companys common stock less market price date option granted options generally become exercisable installments per year first fourth anniversaries grant date maximum term years generally company issues shares stock option exercise treasury stock additionally plan provides granting stock appreciation rights whereby grantee may surrender exercisable rights receive common stock andor cash measured excess market price common stock option exercise price december thousand stock appreciation rights outstanding treated liability awards plan plan provide granting common stock key employees subject restrictions continuous employment restrictions generally expire four year period date grant compensation expense recognized restricted period first quarter company began granting restricted stock units instead restricted stock stock unit right receive stock end specified vesting period stock unit voting rights plan plan also incorporate company 's longterm performance awards awards delivered form target number performance shares three year cycle awards annual goals set beginning performance period based earnings per share sales maximum performance result maximum payout award award addition onetime special performance award granted performance period special performance award annual goals set beginning performance period based pretax operating margin operating cash flow maximum performance result maximum payout goals awards set three year period based cumulative earnings per share cumulative sales ultimate payout modified companys total stockholder return versus companies proxy peer group maximum performance three measures result maximum payout target threshold targets met performance period payment made plan teamshare stock option plan terminated january fulltime employees excluding key executives granted options purchase companys common stock market price date options granted company authorized million shares issuance plan individual grants generally became exercisable evenly third fourth fifth anniversary grant date maximum term years options million shares exercised plan december bristolmyers squibb companys results operations years ended december reflect impact sfas r sharedbased payment includes impact expensing stock options company elected alternative method provided fsp r transition election related accounting tax effects sharebased payment awards determining companys pool excess tax benefits following tables summarize stockbased compensation expense related employee stock options restricted stock longterm performance awards years ended december years ended december dollars millions stock options restricted stock longterm performance shares total stockbased compensation expense stockbased compensation expense recognized consolidated statements earnings follows years ended december dollars millions cost products sold marketing selling administrative research development total stockbased compensation expense deferred tax benefit stockbased compensation expense net taxes stockbased compensation expense million million million included discontinued operations stock options summary stock option activities follows shares common stock weightedaverage shares millions issued plan exercise price shares balance january granted exercised expired forfeited balance december granted exercised expired forfeited balance december granted exercised expired forfeited balance december information related stock option grants exercises plan plan summarized follows year ended december amounts millions except per share data stock options granted weightedaverage grantdate fair value per share total intrinsic value stock options exercised cash proceeds exercise stock options december million total unrecognized compensation cost related stock options expected recognized weightedaverage period years annual report following tables summarize information concerning companys stock compensation plans currently outstanding exercisable options number securities issued upon weightedaverage exercise exercise outstanding options price outstanding shares millions rights options rights plan category equity compensation plans approved security holders equity compensation plans approved security holders shares plan longer issued following table summarizes significant ranges outstanding exercisable options december amounts millions except per share data options outstanding options exercisable weighted average weighted weighted remaining average aggregate average weighted aggregate contractual exercise intrinsic remaining average intrinsic number life price value number contractual life exercise price value range exercise prices outstanding years per share millions exercisable years per share millions vested expected vest aggregate intrinsic value preceding table represents total pretax intrinsic value based companys closing stock price december would received option holders option holders exercised options date total number inthemoney options exercisable december million december million outstanding options exercisable weightedaverage exercise price fair value employee stock options granted estimated date grant using blackscholes option pricing model stock options service condition monte carlo simulation model options service market conditions following table presents weightedaverage assumptions used valuation year ended december expected volatility riskfree interest rate dividend yield expected life yrs yrs yrs company derived expected volatility assumption required blackscholes model calculating year historical volatility weighting equally derived implied volatility selection blended historical implied volatility approach based companys assessment calculation expected volatility representative future stock price trends using historical volatility riskfree interest rate assumption based upon us treasury yield curve effect time grant dividend yield assumption based companys history expectation dividend payouts expected life employee stock options represents weightedaverage period stock options expected remain outstanding derived output latticebinomial model expected life employee stock options impacted underlying assumptions calibration companys model latticebinomial model assumes employees exercise behavior function options remaining vested life extent option inthemoney latticebinomial model estimates bristolmyers squibb probability exercise function two variables based entire history exercises cancellations past option grants made company stockbased compensation expense based awards ultimately expected vest forfeitures estimated based historical experience time grant revised subsequent periods actual forfeitures differ estimates company acquired adnexus october part acquisition agreement company assumed million shares adnexus incentive stock options isos replaced million shares company isos converted options retain original vesting schedules including vesting commencement date well expiration date blackscholes model used determine expected term individual isos valuations result weightedaverage expected term years weightedaverage fair value october restricted stock awards restricted stock units fair value nonvested shares companys common stock determined based average trading price companys common stock grant date restricted share activities follows weightedaverage shares thousands number shares grantdate fair value nonvested shares january granted vested forfeited nonvested shares december granted vested forfeited nonvested shares december granted vested forfeited nonvested shares december expected vest december million total unrecognized compensation cost related nonvested restricted stock cost expected recognized weightedaverage period years total fair value nonvested shares share units granted recognized compensation expense million million million total fair value shares share units vested million longterm performance awards since adoption sfas r fair value performance award estimated date grant using monte carlo simulation model due market condition monte carlo simulation model utilizes multiple input variables determine probability satisfying market condition stipulated award grant calculates fair market value longterm performance awards performance awards theses awards contain market condition fair value based closing trading price companys common stock grant date valuation model award used following assumptions weightedaverage expected riskfree grant year grant date expected volatility dividend yield interest rate weightedaverage expected volatility based three year historical volatility levels companys common stock expected dividend yield based historical dividend payments riskfree interest rate reflects yield five year zero coupon us treasury bonds based performance shares contractual term fair value performance awards amortized performance period award annual report information related performance awards plan plan summarized follows shares thousands performance shares outstanding performance cycle weightedaverage grant date measurement date shares granted grantdate fair value december december annually annually annually annually annually annually total outstanding unrecognized compensation cost related performance share plan million december expected recognized weightedaverage period years accuracy fair value estimates companys determination fair value stockbased payment awards date grant using optionpricing model affected companys stock price well assumptions regarding number highly complex subjective variables variables include limited companys expected stock price volatility term awards actual projected employee stock option exercise behaviors optionpricing models developed use estimating value traded options vesting hedging restrictions fully transferable companys employee stock options certain characteristics significantly different traded options changes subjective assumptions materially affect estimated value managements opinion existing valuation models may provide accurate measure fair value companys employee stock options although fair value employee stock options determined accordance sfas r staff accounting bulletin sab sharebased payment using optionpricing model value may indicative fair value observed willing buyerwilling seller market transaction note financial instruments company exposed market risk due changes currency exchange rates interest rates lesser extent natural gas pricing reduce risk company enters certain derivative financial instruments available costeffective basis hedge underlying economic exposure companys primary net foreign currency translation exposures euro japanese yen canadian dollar chinese renminbi mexican peso manage exposures company utilizes foreign currency contracts subject cash flow hedge accounting treatment instruments managed consolidated basis efficiently net exposures thus take advantage natural offsets company also uses derivative instruments part interest rate risk management strategy derivative instruments used comprised principally fixedtofloating rate interest rate swaps subject fairvalue hedge accounting treatment derivative financial instruments used speculative purposes cash flow hedges foreign exchange contracts company utilizes foreign currency contracts hedge anticipated transactions primarily intercompany transactions certain foreign currencies designates derivative instruments foreign currency cash flow hedges appropriate notional amounts companys foreign exchange derivative contracts december million million respectively derivatives majority qualify hedges future anticipated cash flows effective portion changes fair value temporarily deferred accumulated oci recognized earnings hedged item affects earnings bristolmyers squibb table summarizes companys outstanding foreign exchange forward contracts december fair value foreign exchange forward contracts based yearend currency rates fair value foreign exchange forward contracts viewed relation fair value underlying hedged transactions overall reduction exposure adverse fluctuations foreign currency exchange rates weightedaverage fair value dollars millions except currency rates strike price notional amount assetliability maturity foreign exchange forwards cash flow hedges australian dollar brazilian real british pound canadian dollar euro japanese yen japanese yen mexican peso polish zloty swedish krona swiss franc total cash flow hedges december total notional fair market value contracts buy japanese yen million million respectively fully offset total notional fair market value sell contracts million million respectively december company hold foreign exchange option contracts buy sell japanese yen december balance deferred gains foreign exchange forward contracts qualified cash flow hedge accounting included accumulated oci pretax basis million million net tax expected reclassified earnings within next months sfas accounting derivative instruments hedging activities requires company perform periodic assessments hedge effectiveness company assesses effectiveness inception hedge quarterly basis assessments determine whether derivatives designated qualifying hedges continue highly effective offsetting changes cash flows hedged items ineffective portion fair value longer deferred accumulated oci included current period earnings years ended december impact hedge ineffectiveness earnings significant additionally years ended december impact discontinued hedges pretax gain million pretax loss million million respectively natural gas contracts company utilizes forward contracts hedge anticipated purchase natural gas designates derivative instruments cash flow hedges appropriate derivatives majority qualify hedges future anticipated cash flows effective portion changes fair value temporarily deferred accumulated oci recognized earnings hedged item affects earnings year ended december impact discontinued natural gas hedges pretax loss million material year ended december nonqualifying foreign exchange contracts addition foreign exchange contracts noted company utilizes forward contracts hedge foreign currencydenominated monetary assets liabilities primary objective forward contracts protect us dollar value foreign currency denominated monetary assets liabilities effects volatility foreign exchange rates might occur prior receipt settlement us dollars forward contracts designated hedges marktomarket expense net notional fair value amounts purchased sold foreign exchange forward contracts december material furthermore company uses foreign exchange forward contracts offset exposure certain assets liabilities earnings denominated certain foreign currencies foreign exchange forward contracts designated hedges therefore changes fair value derivatives recognized earnings expense net occur notional fair value amounts foreign exchange forward contracts december material annual report hedge net investment company uses nonus dollar borrowings primarily million notes due million notes due hedge foreign currency exposures companys net investment certain foreign affiliates nonus dollar borrowings designated hedges net investments effective portion foreign exchange gains losses hedges recorded part foreign currency translation component accumulated oci company unhedged exposures net foreign currencydenominated assets liabilities approximately million million december respectively primarily japan china mexico australia uk thailand fair value hedges interest rate contracts company uses derivative instruments part interest rate risk management strategy derivative instruments used comprised principally fixedtofloating rate interest rate swaps subject fairvalue hedge accounting treatment november connection funding retirement fixed rate debt company executed several fixedto floating interest rate swaps convert billion billion billion inception companys newlyissued fixed rate debt paid variable rate debt company executed additional fixedtofloating interest rate swaps convert billion companys newlyissued fixed rate debt paid variable rate total notional amounts outstanding interest rate swaps billion billion billion december billion billion billion december billion billion billion december company recognized net decrease interest expense million net increase million million respectively swaps well underlying debt hedged recorded fair value swaps generally held maturity intended create appropriate balance fixed floating rate debt company swaps qualify fair value hedges terminated prior maturity dates reported part carrying value underlying debt amortized earnings remaining life debt swaps qualify cash flow hedges terminated reported accumulated oci amortized earnings remaining life debt december balance deferred losses forward starting swaps included accumulated oci million reclassified earnings remaining life debt november december company repurchased approximately million principal amount debt terminated million notional amount interest rate swaps resulting gain million reported expense net also company terminated million notional amount fixedtofloating interest rate swap agreements total proceeds million proceeds swap termination recognized interest expense remaining life underlying debt discussion companys debt buyback refer note shortterm borrowings longterm debt following tables summarize interest rate swaps outstanding december earnings impact terminated interest rate swaps interest rate swaps outstanding notio nal amount year fair interest rate swaps underlying debt variable rate received transaction maturity value dollars millions swaps associated notes due month us libor notes due month us libor million notes due month eur euribor million notes due month eur euribor notes due month us libor notes due month us libor notes due month us libor notes due month us libor bristolmyers squibb earnings impact terminated interest rate swaps unrecognized gainslosses pretax incomeexpense recognized year longterm interest rate swaps termination debt comprehensive loss dollars millions interest rate swap lock associated notes due notes due swaps associated notes due notes due notes due notes due notes due notes due notes due notes due following table summarizes companys fair value outstanding derivatives december dollars millions balance sheet location balance sheet location derivatives designated hedging instruments interest rate contracts assets accrued expenses foreign exchange contracts assets accrued expenses hedge net investments shortterm borrowings hedge net investments longterm debt natural gas contracts accrued expenses derivatives designated hedging instruments foreign exchange contracts assets accrued expenses total derivatives impact earnings interest rate swaps qualified fair value hedges years ended december follows dollars millions interest incomeexpense terminated gain recognized expense net total impact oci earnings foreign exchange natural gas forwards qualified cash flow hedges follows foreign exchange natural gas forward starting contracts contracts swap total impact dollars millions gainloss recognized oci december effective portion loss reclassified oci cost products sold effective portion gainloss recognized expense net discontinued ineffective portion annual report impact oci earnings nonderivative debt designated hedge net investment years ended december follows net investment hedges dollars millions loss recognized oci effective portion gain recognized expense net ineffective portion amount excluded effectiveness testing impact earnings nonqualifying derivatives years ended december follows dollars millions gain recognized expense net discussion fair value financial instruments see note fair value measurement discussion cash cash equivalents marketable securities see note cash cash equivalents marketable securities longterm debt difference fair value carrying value material january company terminated fixedtofloating interest rate swaps notional amount million resulting million gain amortized remaining life debt note segment information segment information consistent management reviews businesses makes investing resource allocation decisions assesses operating performance company reports financial operating information two segmentspharmaceuticals nutritionals pharmaceuticals segment comprised global pharmaceutical international consumer medicines businesses nutritionals segment consists mead johnson primarily infant formula business childrens nutritional business january august company completed divestiture medical imaging convatec businesses respectively results medical imaging convatec businesses previously included former health care convatec operating segments respectively included discontinued operations additional information divestitures medical imaging convatec see note acquisitions divestitures note discontinued operations assets held sale companys products sold principally wholesale retail trade nationally internationally certain products also sold drug manufacturers hospitals clinics government agencies medical profession gross sales three pharmaceutical wholesalers us accounted approximately companys total gross sales companys total gross sales companys total gross sales earnings continuing operations net sales income taxes minority interest yearend assets dollars millions pharmaceuticals nutritionals total segments corporateother total bristolmyers squibb corporateother assets include cash cash equivalents marketable securities assets discontinued operations certain assets earnings continuing operations income taxes minority interest reported corporateother consists dollars millions corporate administrative expense stockbased compensation expense provision restructuring net litigation expense net interest expense interest income ars impairment charge gain sale imclone shares gain sale product lines businesses gainloss debt buyback termination interest rate swap agreements total corporateother earnings continuing operations income taxes minority interest net sales companys key products follows net sales products dollars millions pharmaceuticals plavix avaproavalide pravachol reyataz sustiva franchise total revenue baraclude erbitux taxol sprycel ixempra abilify orencia pharmaceuticals total pharmaceuticals nutritionals enfamil nutritionals total nutritionals total companys capital expenditures depreciation follows capital expenditures depreciation dollars millions pharmaceuticals nutritionals total segments corporateother total corporateother amounts include activities convatec medical imaging businesses including capital expenditures million million million depreciation expense million million million annual report companys selected geographic area information follows net sales yearend assets dollars millions united states europe middle east africa western hemisphere pacific total note leases minimum rental commitments noncancelable operating leases primarily real estate motor vehicles effect december follows years ending december dollars millions later years total minimum payments less total minimum sublease rentals net minimum rental commitments operating lease rental expense million million million net sublease rental income million million million february company completed sale leaseback administrative facility paris france million million resulting pretax gain transaction million million deferred reduce future lease rental costs lease period years december company completed sale leaseback several administrative facilities new jersey million resulting pretax gain transaction million million deferred reduce future lease rental costs lease periods ranging years bristolmyers squibb note pension postretirement postemployment liabilities company certain subsidiaries defined benefit pension plans defined contribution plans termination indemnity plans regular fulltime employees principal pension plan bristolmyers squibb retirement income plan us represents approximately companys total pension plan assets obligations funding policy contribute amounts provide current service fund past service liability plan benefits based primarily participants years credited service compensation plan assets consist principally equity fixedincome securities company also provides comprehensive medical group life benefits substantially us retirees elect participate comprehensive medical group life plans medical plan contributory contributions adjusted periodically vary date retirement original retiring company life insurance plan noncontributory plan assets consist principally equity fixedincome securities similar plans exist employees certain countries outside us net periodic benefit cost companys defined benefit pension postretirement benefit plans included following components pension benefits benefits dollars millions service cost benefits earned year interest cost projected benefit obligation expected return plan assets amortization prior service costbenefit amortization net actuarial loss amortization transitional obligation net periodic benefit cost curtailments settlements special termination benefits total net periodic benefit cost total net periodic benefit costs recognized follows pension benefits benefits dollars millions continuing operations discontinued operations total net periodic benefit cost estimated net actuarial loss prior service cost amortized accumulated oci net periodic benefit cost dollars millions pension benefits benefits amortization net actuarial loss amortization prior service costbenefit annual report changes benefit obligations plan assets funded status amounts recognized balance sheet years ended december companys defined benefit postretirement benefit plans follows pension benefits benefits dollars millions benefit obligation beginning year service costbenefits earned year interest cost projected benefit obligation plan participants contributions curtailments settlements actuarial assumptions lossesgains plan amendments retiree drug subsidy received benefits paid special termination benefits exchange rate gainslosses benefit obligation end year fair value plan assets beginning year actual return plan assets employer contribution plan participants contributions settlements retiree drug subsidy received benefits paid exchange rate lossesgains fair value plan assets end year funded status amounts recognized consolidated balance sheets consist assets accrued expenses pension postretirement liabilities accrued benefit cost net amount recognized amounts recognized accumulated comprehensive loss net actuarial loss net obligation adoption prior service costbenefit net amount recognized impact medicare prescription drug improvement modernization act million million million reflected reduction accumulated postretirement benefit obligation accumulated benefit obligation defined benefit pension plans million million december respectively information related companys pension plans december follows dollars millions pension plans projected benefit obligations excess plan assets projected benefit obligation fair value plan assets pension plans accumulated benefit obligations excess plan assets accumulated benefit obligation fair value plan assets bristolmyers squibb actuarial assumptions weightedaverage assumptions used determine benefit obligations december follows pension benefits benefits discount rate rate compensation increase weightedaverage actuarial assumptions used determine net periodic benefit cost years ended december follows pension benefits benefits discount rate expected longterm return plan assets rate compensation increase company uses yield high quality corporate bonds matches duration benefit obligations determining discount rate citigroup median yield curve used developing discount rate us plans company considers several factors developing expected return plan assets longterm historical returns input external advisors individual asset class return forecasts developed based upon market conditions example price earnings levels yields longterm growth expectations expected longterm rate return weightedaverage target asset allocation individual asset class longterm expected rate return plan assets us plans included active management premium approximately projected market returns received external advisors companys longterm expected annualized returns us pension plans follows years years years expected return plan assets determined using expected rate return calculated value assets referred marketrelated value marketrelated value exceeds fair value plan assets approximately billion december less fair value plan assets approximately million december change primarily driven significant losses incurred plan assets due current market conditions differences assumed actual returns amortized marketrelated value straightline basis three year period gains losses resulted changes actuarial assumptions changes discount rate differences assumed actual experience differences actual assumed returns plan assets gains losses except differences amortized marketrelated value amortized extent exceed higher marketrelated value projected benefit obligation respective plan result approximately billion related pension benefits expected amortized remaining actuarial losses amortized expected remaining service periods active participants assumed health care cost trend rates december follows health care cost trend rate assumed next year rate cost trend rate assumed decline ultimate trend rate year rate reaches ultimate trend rate annual report assumed health care cost trend rates effect amounts reported health care plans onepercentagepoint change assumed health care cost trend rates would following effects percentage percentagepoint dollars millions point increase decrease effect total service interest cost effect postretirement benefit obligation plan assets companys asset allocation december follows pension benefits benefits publicly traded equity securities debt securities including cash private equity total companys investment strategy emphasizes equities order achieve high expected returns long run low expense low required cash contributions us pension plans target asset allocation public equity us international private equity fixed income maintained cash flow ie cash contributions benefit payments used rebalance back targets necessary investments well diversified within three major asset categories approximately us equity investments actively managed investment strategies international pension plans typically similar although asset allocations usually conservative private equity valued three month lag bristolmyers squibb company common stock represents less plan assets december contributions contributions us pension plans million million million contributions us pension plans expected approximately million million contributed january contributions international pension plans million million million contributions international plans expected range million million estimated future benefit payments following benefit payments mainly us pension plans reflect expected future service appropriate expected paid benefits medicare dollars millions pension benefits gross subsidy net years bristolmyers squibb adoption sfas company adopted sfas employers accounting defined benefit pension postretirement plansan amendment fasb statements r year ended december resulting million reduction accumulated oci stockholders equity million reduction total assets million increase total liabilities impact adoption summarized follows sfas adjustments dollars millions presfas pretax tax net postsfas current assets deferred income taxes noncurrent assets deferred income taxes prepaid pension assets current liabilities accrued expenses us foreign income taxes payable noncurrent liabilities liabilities stockholders equity accumulated comprehensive loss savings plan principal defined contribution plan bristolmyers squibb savings investment program companys contribution based employee contributions level company match companys contributions plan million million million post employment benefit plan company offers longterm disability benefits certain employees post employment liabilities million million december respectively expense related benefits million million million termination indemnity plans company operates certain jurisdictions primarily europe require recording statutory termination obligations obligations recognized undiscounted basis assuming employee termination measurement date total pension liability recorded obligations million december million december annual report note legal proceedings contingencies various lawsuits claims proceedings investigations pending involving company certain subsidiaries accordance sfas accounting contingencies company records accruals contingencies probable liability incurred amount loss reasonably estimated matters involve antitrust securities patent infringement pricing sales marketing practices environmental health safety matters consumer fraud employment matters product liability insurance coverage significant litigation charges million million million net revised estimates previously accrued amounts cash payments related significant litigation million million million significant matters described assurance increase scope pending matters future lawsuits claims proceedings investigations material intellectual property plavix litigation plavix currently companys largest product ranked net sales plavix patents subject number challenges us including litigation apotex inc apotex corp apotex described less significant markets product possible reasonably estimate impact lawsuits company however loss market exclusivity plavix sustained generic competition us would material companys sales plavix results operations cash flows could material companys financial condition liquidity company product partner sanofi companies intend vigorously pursue enforcement patent rights plavix plavix litigation us patent infringement litigation apotex related matters previously disclosed companys us territory partnership alliance sanofi plaintiff pending patent infringement lawsuit instituted united states district court southern district new york district court entitled sanofi synthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceuticals holding partnership v apotex suit based us patent patent composition matter patent discloses claims among things hydrogen sulfate salt clopidogrel medicine made available us companies plavix also previously reported district court upheld validity enforceability patent maintaining main patent protection plavix us november district court also ruled apotexs generic clopidogrel bisulfate product infringed patent permanently enjoined apotex engaging activity infringes patent including marketing generic product us patent expires apotex appealed district courts decision december united states court appeals federal circuit circuit court affirmed district courts ruling sustaining validity patent apotex filed petition circuit court rehearing en banc petition pending district court stayed certain antitrust counterclaims brought apotex pending final outcome appeal previously disclosed companys us territory partnership alliance sanofi also plaintiff five additional pending patent infringement lawsuits dr reddys laboratories inc dr reddys laboratories ltd dr reddys teva pharmaceuticals usa inc teva cobalt pharmaceuticals inc cobalt watson pharmaceuticals inc watson laboratories inc watson sun pharmaceuticals sun lawsuits dr reddys teva cobalt relate patent trial date action dr reddys set january court entered order requires dr reddys give company business days notice intent launch patent infringement actions teva cobalt stayed pending resolution apotex litigation parties actions agreed bound outcome litigation apotex although teva cobalt appeal outcome litigation consequently july district court entered judgments cobalt teva permanently enjoined cobalt teva engaging activity infringes patent patent expires cobalt teva filed appeal lawsuit watson filed october based us patent patent discloses claims particular crystalline polymorph form hydrogen sulfate salt clopidogrel marketed plavix december court permitted watson pursue declaratory judgment counterclaim respect us patent january court approved parties stipulation stay case pending outcome trial apotex matter april pharmastar filed request inter partes reexamination patent us patent trademark office granted request july thus patent currently reexamination lawsuit sun filed july based infringement patent patent respect patent sun bristolmyers squibb agreed bound outcome apotex litigation although sun like teva cobalt appeal outcome litigation dr reddys teva cobalt watson sun filed anda fda exclusivity periods statutory stay periods hatchwaxman act expired accordingly final approval fda would provide company authorization distribute generic clopidogrel bisulfate product us subject various legal remedies companies may apply including injunctive relief damages previously disclosed march company served civil investigative demand ftc requesting documents information related proposed settlement company ftc currently discussions regarding potential resolution matter addition previously disclosed april company received subpoena new york state attorney generals office antitrust bureau nyag documents related proposed settlement december company entered settlement agreement nyag behalf states pursuant company agreed pay million resolve states claims possible time reasonably assess outcomes appeal apotex circuit courts decision plavix patent litigations timing renewed generic competition plavix apotex additional generic competition plavix thirdparty generic pharmaceutical companies however apotex prevail appeal patent litigation company would expect face renewed generic competition plavix promptly thereafter loss market exclusivity plavix andor sustained generic competition would material companys sales plavix results operations cash flows could material companys financial condition liquidity additionally possible time reasonably assess amount damages could recovered company apotexs ability pay damages event company prevails apotexs appeal district court decision additionally november apotex filed lawsuit new jersey superior court entitled apotex inc et al v sanofiaventis et al seeking payment million plus interest related breakup proposed settlement agreement december defendants removed case federal district court new jersey apotex moved remand case back state court plavix litigation international plavix canada apotex inc previously disclosed sanofisynthelabo sanofisynthelabo canada inc instituted prohibition action federal court canada apotex minister health response notice allegation noa apotex directed canadian patent patent covering clopidogrel bisulfate apotexs noa indicated filed abbreviated new drug submission ands clopidogrel bisulfate tablets sought approval notice compliance ands expiration patent scheduled august apotexs noa alleged patent invalid infringed march canadian federal court ottawa rejected apotexs challenge canadian plavix patent held asserted claims novel obvious infringed granted sanofis application order prohibition minister health apotex order prohibition precludes approval apotexs ands patent expires unless federal courts decision reversed appeal apotex filed appeal december federal court appeal dismissed apotexs appeal upheld federal courts issuance order prohibition february apotex filed leave appeal decision supreme court canada granted july biotecanada canadian generic pharmaceutical association canadas researchbased pharmaceutical companies granted leave intervene november supreme court canada dismissed apotexs appeal federal court appeal decision upheld validity patent order prohibition also previously disclosed april apotex filed lawsuit canada ontario superior court justice entitled apotex inc et al v sanofiaventis et al seeking payment million plus interest related breakup proposed settlement agreement january court granted defendants motions dismiss grounds forum non conveniens subject matter jurisdiction apotex appealed decision court appeal ontario october court appeal dismissed lawsuit apotex appeal supreme court canada instead november apotex filed lawsuit new jersey superior court described plavix canada cobalt previously disclosed sanofi sanofisynthelabo canada instituted prohibition action federal court canada cobalt minister health response noa cobalt directed patent canadian patent patent cobalts noa indicated filed ands clopidogrel bisulfate tablets sought notice compliance ands expiration patents cobalt alleged patent invalid patent invalid infringed following supreme court canada decision apotex inc v sanofisynthelabo canada annual report inc scc dismissing apotexs appeal upholding validity patent described federal court canada granted sanofis application order prohibition minister health cobalt precluding approval cobalts ands patent expires sanofi pursue prohibition action respect patent plavix korea previously disclosed june korean intellectual property tribunal kipt invalidated claims sanofis korean patent including claims directed clopidogrel pharmaceutically acceptable salts clopidogrel bisulfate sanofi appealed january patent court affirmed kipt decision company sanofi filed appeal supreme court korea sanofi also commenced infringement actions generic pharmaceutical companies launched generic clopidogrel bisulfate received approval alternate salt forms clopidogrel korea possible time reasonably assess outcome lawsuits impact company plavix australia previously disclosed sanofi notified august genrx proprietary limited genrx obtained regulatory approval application clopidogrel bisulfate mg tablets australia genrx formerly subsidiary apotex since changed name apotex august apotex filed application federal court australia seeking revocation sanofis australian patent case nsd sanofi filed counterclaims infringement sought injunction september australian court granted sanofis injunction subsidiary company subsequently added party proceedings february second company spirit pharmaceuticals pty ltd also filed revocation suit patent case consolidated apotex case trial occurred april august federal court australia held claims patent covering clopidogrel bisulfate hydrochloride hydrobromide taurocholate salts valid federal court also held process claims pharmaceutical composition claims claim directed clopidogrel pharmaceutically acceptable salts invalid view decision possible generic company could develop seek registration australia alternate salt form clopidogrel bisulfate hydrochloride hydrobromide taurocholate company sanofi filed notices appeal full court federal court australia appealing holding invalidity claim covering clopidogrel pharmaceutically acceptable salts process claims pharmaceutical composition claims stayed federal courts ruling apotex filed notice appeal appealing holding validity clopidogrel bisulfate hydrochloride hydrobromide taurocholate claims hearing appeals occurred february decision pending plavix germany previously disclosed yes pharmaceutical development services gmbh yes pharmaceutical filed application marketing authorization germany alternate salt form clopidogrel application relied data studies originally conducted sanofi bms plavix may german health authority bfarm granted marketing authorization yes pharmaceutical product data protection plavix expire july sanofi bms filed objection grant marketing authorization grounds data exclusivity rights infringed yes pharmaceutical partners sought immediate enforcement marketing authorization denied bfarm yes pharmaceutical partners filed legal motion immediate enforcement administrative court granted yes pharmaceuticals partners hexal ratiopharm began continue market product germany sanofi bms appealed decision administrative court appeal rejected administrative appeal court third party objection bfarm dismissed bfarm sanofi bms appealed decision administrative court cologne matter currently pending yes pharmaceutical partners announced plan seek marketing authorization eu countries addition germany also company believes companies filed approvals eu clopidogrel containing product applications pending intellectual property litigation abilify previously disclosed otsuka filed patent infringement actions teva barr pharmaceuticals inc barr sandoz inc sandoz synthon laboratories inc synthon sun pharmaceuticals sun apotex relating us patent covers aripiprazole expires october aripiprazole comarketed company otsuka us abilify lawsuits currently pending us district court district new jersey possible time reasonably assess outcome lawsuits impact company bristolmyers squibb erbitux previously disclosed february abbott laboratories abbott filed suit imclone us district court district massachusetts alleging imclones manufacture sale erbitux infringe us patent patent seeking damages alleged infringement pursuant settlement sublicensing agreements executed imclone repligen corporation repligen announced september repligen granted imclone royaltyfree irrevocable worldwide sublicense future use patented technology including patent owned abbott licensed repligen agreement abbott repligen september imclone abbott executed written settlement agreement ending litigation pending parties terms settlement agreement imclone paid abbott million full final settlement claims counterclaims companys commercial agreements imclone include provisions pursuant certain financial consequences company resulting settlement sublicensing agreements would responsibility imclone possible time assess outcome lawsuit potential impact company enfamil september company whollyowned subsidiary mead johnson co filed patent infringement lawsuit abbott laboratories abbott nutrition abbott us district court southern district indiana infringement us patent companies allege abbotts sale certain cans similac infant formula powder infringes patent february companies entered settlement agreement resolving matter general commercial litigation clayworth litigation previously disclosed company together number pharmaceutical manufacturers named defendant action filed california state superior court oakland james clayworth et al v bristolmyers squibb company et al alleging defendants conspired fix prices pharmaceuticals agreeing charge drugs us charge outside us particularly canada asserting claims californias cartwright act unfair competition law plaintiffs sought trebled monetary damages injunctive relief relief december court granted company manufacturers motion summary judgment based passon defense judgment entered favor defendants july judgment favor defendants affirmed california court appeals november california supreme court granted plaintiffs petition review possible time reasonably assess outcome lawsuit impact company event plaintiffs successful appeal rxusa wholesale litigation previously disclosed july complaint filed drug wholesaler rxusa wholesale inc us district court eastern district new york company drug manufacturers five drug wholesalers two officers defendant mckesson wholesale distribution industry trade group rxusa wholesale inc v alcon labs inc et al complaint alleges violations federal new york antitrust laws well various laws plaintiff claims defendants allegedly engaged anti competitive acts resulted exclusion plaintiff relevant market seeks million damages trebling relief company together manufacturer defendants filed motion dismiss case november motion remains pending court possible time reasonably estimate outcome lawsuit impact company antitrust litigation previously disclosed lawsuits comprised individual suits purported class actions filed company us district court southern district ohio western division various plaintiffs including pharmacy chains individually assignees whole part certain wholesalers various health welfare benefit plansfunds individual residents various states lawsuits allege among things purported settlement apotex patent infringement litigation violated sherman act related laws plaintiffs seeking among things permanent injunctive relief barring apotex settlement andor monetary damages putative class actions filed behalf direct purchasers consolidated caption plavix direct purchaser antitrust litigation putative class actions filed behalf indirect purchasers consolidated caption plavix indirect purchaser antitrust litigation amended complaints filed october defendants filed consolidated motion dismiss december remains pending possible time reasonably assess outcome lawsuits impact company annual report shareholder derivative actions previously disclosed july certain members board directors current former officers company named two derivative actions filed new york state supreme court john frank v peter dolan et al donald beebout v peter dolan et al one derivative action filed federal district court steven w sampson v james robinson iii et al cv complaints allege breaches fiduciary duties allegedly failing disclose material information relating efforts settle plavix patent infringement litigation apotex plaintiffs seek monetary damages behalf company contribution indemnification decision filed december state court granted motions dismiss complaints frank beebout relating certain members board directors dismiss complaints former officers decision dated august federal district court granted companys motion dismiss sampson action plaintiffs appealed district courts decision us circuit court appeals second circuit pending securities litigation bristolmyers squibb co securities litigation previously disclosed june july two putative class action complaints minneapolis firefighters relief assoc v bristol myers squibb co et al cv jean lai v bristolmyers squibb company et al filed us district southern district new york company companys former chief executive officer peter dolan former chief financial officer andrew bonfield complaints allege violations securities laws allegedly failing disclose material information relating efforts settle plavix patent infringement litigation apotex september court dismissed lai case without prejudice changed caption case bristolmyers squibb co securities litigation appointed ontario teachers pension plan board lead plaintiff october ontario teachers pension plan board filed amended complaint making similar allegations earlier filed complaints naming additional former officer longer naming andrew bonfield defendant decision dated august federal district court denied defendants motions dismiss company intends defend vigorously litigation possible time reasonably assess outcome lawsuits potential impact company pricing sales promotional practices litigation investigations awp litigation previously disclosed company together number pharmaceutical manufacturers defendant number private class actions well suits brought attorneys general various states actions plaintiffs allege defendants caused average wholesale prices awps products inflated thereby injuring government programs entities persons reimbursed prescription drugs based awps company remains defendant five state attorneys general suits pending federal state courts around country previously reported one set class actions together suit arizona attorney general consolidated us district court district massachusetts awp mdl court awp mdl certified three classes persons entities paid reimbursed seven companys physicianadministered drugs june company settled principle claims class medicare part b beneficiaries nationwide million plus half costs class notice maximum payment million parties finalizing terms settlement hearing scheduled preliminary approval class settlement june nonjury trial awp mdl court found company liable violations massachusetts consumer protection laws respect certain oncology drugs certain years awarded damages amount thousand plus interest class private thirdparty payors instructed parties apply courts opinion determine damages class medigap insurers august court found damages thousand plus interest class company appealed june decision us court appeals first circuit oral arguments heard november september court awp mdl issued order certifying multistate classes class class possible time reasonably assess outcome litigation matters described potential impact company bristolmyers squibb california b litigation previously disclosed august county santa clara filed purported class action company numerous pharmaceutical manufacturers behalf putative class cities counties california well covered entities purchased drugs pursuant b drug discount program july us district court northern district california dismissed lawsuit prejudice failure state claim plaintiff appealed us court appeals ninth circuit september ninth circuit reversed district courts dismissal reinstated lawsuit possible time reasonably assess outcome lawsuit potential impact company product liability litigation company party various product liability lawsuits addition lawsuits company also faces unfiled claims involving products time company believe ongoing lawsuits likely result material effect companys financial results operations however company also aware potential unfiled claims possible time reasonably assess outcome additional lawsuits might filed potential impact company company certain affiliates sanofi defendants number individual lawsuits claiming personal injury allegedly sustained using plavix appear united states district court district new jersey nj district court nj district court ordered administrative termination cases pending resolution potentially related issues united state supreme court cases involving prescription drugs preemption defendants executed tolling agreements respect unfiled claims potential additional plaintiffs possible time reasonably asses outcomes lawsuits impact company environmental proceedings previously reported company party several environmental proceedings matters responsible various state federal foreign laws including comprehensive environmental response compensation liability act cercla certain costs investigating andor remediating contamination resulting past industrial activity companys current former sites waste disposal reprocessing facilities operated third parties cercla matters respect cercla matters company responsible various state federal foreign laws company typically estimates potential costs based information obtained us environmental protection agency epa counterpart state agency andor studies prepared independent consultants including total estimated costs site expected cost sharing potentially responsible parties company accrues liabilities probable reasonably estimable december company estimated share total future costs sites approximately million recorded liabilities represents sum best estimates simple estimate reasonably made estimates minimal probable amount among range costs without taking account potential recoveries parties currently expected passaic river nj remediation natural resource damages claims previously disclosed september new jersey department environmental protection njdep issued administrative enforcement directive requiring company companies perform assessment natural resource damages implement unspecified interim remedial measures restore conditions lower passaic river lpr directive named company due releases nearby bulk chemical reprocessing facility operated predecessor mckesson corp subsequently epa issued notice letters numerous parties company requesting performance remedial investigationfeasibility study rifs conditions lpr consent agreement epa group parties committed pay roughly half million estimated rifs epa time epa thereafter substantially increased estimate scope cost rifs result epa agreed allow group perform remaining rifs tasks groups estimate total costs complete rifs related tasks exceed million group negotiated amended consent agreement epa conduct remaining rifs work became effective may part process company mckesson bought remaining rifs tasks annual report separately company agreed pay approximately thousand towards rifs tasks previously funded mckesson work cooperatively going forward subject later reallocation mid epa announced plans seek implementation earlyaction remedial measures address highlycontaminated portions lpr rifs completed epa indicated expects select actions early also subgroup cooperating private parties commenced discussions federal natural resource trustee agencies concerning agreement assess natural resource damages lpr discussions expected continue mid remaining parties including company mckesson declined discuss proposal least scope cost earlyactions sought epa thoroughly understood extent liability company may face related requirements yet determined north brunswick township board education previously disclosed october company contacted counsel representing north brunswick nj board education boe regarding site waste materials er squibb sons may disposed fill material containing industrial waste heavy metals excess residential standards discovered expansion project north brunswick township high school well number neighboring residential properties adjacent public park areas january njdep sent company others information request letter possible waste disposal site company responded march boe township current owners school property park conducting jointly financing soil remediation work ground water investigation work work plan approved njdep asked company contribute cost company actively monitoring cleanup project including costs date neither school board township asserted claim company instead company local entities negotiated agreement attempt resolve matter informal means including mediation binding allocation necessary central component agreement provision company interim funding help defray cleanup costs assure work interrupted company transmitted initial interim funding payment december parties since commenced mediation activities expected conclude mid ods regulatory compliance previously disclosed epa investigating industrial commercial facilities throughout us use refrigeration equipment containing ozonedepleting substances ods enforcing compliance regulations governing prevention service repair leaks ods requirements company performed voluntary corporatewide audit facilities us puerto rico use odscontaining refrigeration equipment company submitted audit report epa november identifying potential violations ods requirements several facilities addition matters covered companys audit report letter epa epa previously sent mead johnson request information regarding compliance ods requirements facility evansville indiana company responded request june result identified potential violations evansville facility company signed consent decree epa resolve potential violations discovered audit identified result epa request information evansville facility filed evansville division us district court southern district indiana july consent decree requires company pay civil penalty thousand retire retrofit replace odscontaining refrigeration units june located facilities new jersey indiana puerto rico consent decree also requires company spend least thousand supplemental environmental project consists removal two odscontaining comfort cooling devices new brunswick nj facility tie functions new centralized chiller system use ods refrigerant consent decree yet entered court new brunswick facility environmental personal injury lawsuits previously disclosed may approximately lawsuits filed company superior court middlesex county nj behalf current former residents new brunswick nj live adjacent companys new brunswick facility complaints allege various personal injuries property damage resulting soil groundwater contamination property stemming historical operations new brunswick facility complaints also allege bms failed remediate contamination new brunswick facility compliance state federal cleanup requirements new brunswick facility already undergoing environmental remediation part new jersey department environmental protection njdep approved cleanup plan addition lawsuits plaintiffs filed notice seeking relief nj environmental rights act october new jersey supreme court granted mass tort status cases transferred new jersey superior court atlantic county centralized case management purposes company filed motions dismiss lawsuits denied leave refile discovery taken others still pending court company intends defend vigorously litigation possible time reasonably assess outcome lawsuits potential impact company bristolmyers squibb wage hour litigation previously disclosed putative class action complaint filed company former sales representatives beth amendola v bristolmyers squibb company et al docket cv filed june district court plaintiff alleges company violated federal fair labor standards act among things paying overtime compensation putative class similarly situated sales employees june court issued decision renders case nonclass action lawsuit company settled lawsuit individual plaintiffs settlement agreement material company concludes lawsuit proceedings sec germany investigation previously disclosed october sec notified company conducting informal inquiry activities certain companys german pharmaceutical subsidiaries employees andor agents october sec informed company inquiry formal secs inquiry encompasses matters currently investigation german prosecutor munich germany company understands inquiry investigation concern potential violations foreign corrupt practices act german law respectively company cooperating sec german authorities company established accrual respect investigation german prosecutor possible time reasonably assess outcome investigations impact company convatec italy investigation previously reported italian competition authorities investigated complaint lodged hospital ferrara region italy relating allegation four medical device companies including convatec boycotted tenders ferrara tenders may convatec received statement objections italian competition authorities whereby authorities alleged four medical device companies including convatec acted concerted manner regard ferrara tenders tenders pricing discussions three regions acted way prevent competition throughout italy august competition authorities issued decision found four medical device companies infringed italian antitrust law participating ferrara tenders imposed fine convatec amount material company convatec division bms italy prior divestiture fine imposed bms italy convatec appealed decision administrative court fine imposed convatec later reduced company appealed decision high court second instance consiglio di stato hearing occurred february annual report note selected quarterly financial data unaudited dollars millions except per share data first quarter second quarter third quarter fourth quarter year net sales gross margin net earnings continuing operations net earnings discontinued operations net net earnings earnings per common share basic net earnings continuing operations net earnings discontinued operations net net earnings per common share diluted net earnings continuing operations net earnings discontinued operations net net earnings per common share dividends declared per common share cash cash equivalents marketable securities dollars millions except per share data first quarter second quarter third quarter fourth quarter year net sales gross margin net earningsloss continuing operations net earnings discontinued operations net net earningsloss earnings per common share basic net earningsloss continuing operations net earnings discontinued operations net net earningsloss per common share diluted net earningsloss continuing operations net earnings discontinued operations net net earningsloss per common share dividends declared per common share cash cash equivalents marketable securities earnings per share quarters may add amounts year period computed discrete basis bristolmyers squibb company recorded following specified expenseincome items affected comparability results first second third fourth dollars millions quarter quarter quarter quarter year productivity transformation initiative downsizing streamlining worldwide operations accelerated depreciation asset impairment shutdown costs pension settlementscurtailments process standardization implementation costs gain sale leaseback properties termination lease contracts gain sale product lines businesses litigation settlement insurance recovery mead johnson charges product liability upfront milestone payments acquired inprocess research development asset impairment ars impairment charges gainloss sale debt buyback swap terminations gain sale imclone shares income taxes items decreaseincrease net earnings continuing operations first second third fourth dollars millions quarter quarter quarter quarter year productivity transformation initiative downsizing streamlining worldwide operations accelerated depreciation asset impairment process standardization implementation costs litigation settlement insurance recovery product liability upfront milestone payments acquired inprocess research development ars impairment charges downsizing streamlining worldwide operations accelerated depreciation asset impairment contract termination gain sale properties product lines businesses income taxes items change estimate taxes prior year specified item decreaseincrease net earnings continuing operations annual report following table reconciles previously reported data current year quarterly data updated discontinued operations related convatec disposition see note discontinued operations assets held sale first quarter fourth quarter first quarter adjusted reported adjusted reported adjusted reported previously convatec december previously convatec december previously convatec december dollars millions except per share data reported disposition k reported disposition k reported disposition k net sales gross margin net earnings continuing operations net earnings discontinued operations net net earnings earnings per common share basic net earnings continuing operations net earnings discontinued operations net net earnings per common share diluted net earnings continuing operations net earnings discontinued operations net net earnings per common share bristolmyers squibb reports management managements responsibility financial statements management responsible preparation integrity financial information presented annual report accompanying consolidated financial statements prepared conformity accounting principles generally accepted united states america gaap applying certain estimates judgments required managements opinion consolidated financial statements present fairly companys financial position results operations cash flows audit committee board directors meets regularly internal auditors deloitte touche llp dt companys independent registered accounting firm management review accounting internal control structure financial reporting matters internal auditors dt full free access audit committee set forth companys standard business conduct ethics company firmly committed adhering highest standards moral ethical behavior business activities managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting supervision participation management including chief executive officer chief financial officer management assessed effectiveness internal control financial reporting december based framework internal controlintegrated framework issued committee sponsoring organizations treadway commission based assessment management concluded companys internal control financial reporting effective december provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance accounting principles generally accepted united states america gaap due inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate deloitte touche llp independent registered public accounting firm audited companys financial statements included annual report issued report managements assessment effectiveness companys internal control appears annual report james cornelius chairman chief executive officer jeanmarc huet chief financial officer february annual report controls procedures evaluation disclosure controls procedures december management carried evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure controls procedures term defined exchange act rule ae based evaluation management concluded december disclosure controls procedures effective managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting supervision participation management including chief executive officer chief financial officer management assessed effectiveness internal control financial reporting december based framework internal controlintegrated framework issued committee sponsoring organizations treadway commission based assessment management concluded companys internal control financial reporting effective december provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance united states generally accepted accounting principles due inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate deloitte touche llp independent registered public accounting firm audited companys financial statements included annual report issued report effectiveness companys internal control financial reporting december included herein changes internal control financial reporting changes companys internal control financial reporting quarter ended december materially affected reasonably likely materially affect companys internal control financial reporting information february mead johnson company mjc borrower mead johnson nutrition company mead johnson guarantor indirect majorityowned subsidiaries company entered three year syndicated revolving credit facility agreement credit facility financial institutions lenders named therein including jpmorgan chase bank na jpmcb administrative agent credit facility unsecured repayable maturity february subject annual extensions sufficient lenders agree maximum amount outstanding borrowings letters credit permitted one time credit facility million amount may increased time time million request mjc subject customary conditions contained credit facility proceeds credit facility used working capital general corporate purposes mead johnson subsidiaries including commercial paper backup repurchase shares borrowings credit facility bear interest either libor rate specified interest periods plus margin determined reference companys consolidated leverage ratio b floating rate based upon jpmcbs prime rate federal funds rate libor rate plus case margin determined reference companys consolidated leverage ratio company also paying customary facility structuring syndication administration fees mead johnson guaranteed obligations mjc subsidiary borrowers credit facility additional subsidiaries mead johnson may become borrowers credit facility case mead johnson mjc guaranty obligations subsidiary credit facility credit facility contains customary covenants including covenants applicable mead johnson subsidiaries limiting liens substantial asset sales mergers restrictions subject certain minimum thresholds exceptions credit facility also contains following financial covenants mead johnson required maintain ratio consolidated total debt ii consolidated ebitda greater compliance covenant tested last day fiscal quarter condition precedent credit extension credit facility b mead johnson required maintain ratio consolidated ebitda ii consolidated interest expense least compliance covenant tested last day fiscal quarter preceding four consecutive fiscal quarters addition credit facility customary events default including subject certain materiality thresholds grace periods payment default failure comply covenants material inaccuracy representation warranty bankruptcy insolvency proceedings change control erisa matters crossdefault debt agreements bristolmyers squibb report independent registered public accounting firm board directors stockholders bristolmyers squibb company audited accompanying consolidated balance sheets bristolmyers squibb company subsidiaries company december related consolidated statements earnings comprehensive income retained earnings cash flows three years period ended december financial statements responsibility company 's management responsibility express opinion financial statements based audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidated financial statements present fairly material respects financial position bristolmyers squibb company subsidiaries december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america discussed notes consolidated financial statements company adopted financial accounting standards board interpretation fin accounting uncertainty income taxes interpretation fasb statement effective january statement financial accounting standards sfas employers accounting defined benefit pension postretirement plans amendment fasb statements r effective december also audited accordance standards public company accounting oversight board united states company 's internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission report dated february expressed unqualified opinion company 's internal control financial reporting deloitte touche llp parsippany new jersey february annual report report independent registered public accounting firm board directors stockholders bristolmyers squibb company audited internal control financial reporting bristolmyers squibb company subsidiaries company december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission company 's management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying managements report internal control financial reporting responsibility express opinion company 's internal control financial reporting based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion company 's internal control financial reporting process designed supervision company 's principal executive principal financial officers persons performing similar functions effected company 's board directors management personnel provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles company 's internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition company 's assets could material effect financial statements inherent limitations internal control financial reporting including possibility collusion improper management override controls material misstatements due error fraud may prevented detected timely basis also projections evaluation effectiveness internal control financial reporting future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission also audited accordance standards public company accounting oversight board united states consolidated financial statements year ended december company report dated february expressed unqualified opinion financial statements deloitte touche llp parsippany new jersey february bristolmyers squibb five year financial summary amounts millions except per share data income statement data net sales earning continuing operations income taxes minority interest net earnings continuing operations net earnings continuing operations per common share basic diluted average common shares outstanding basic diluted dividends paid common preferred stock dividends declared per common share financial position data december total assets cash cash equivalents marketable securities longterm debt stockholders equity company recorded items affected comparability results discussion items years see managements discussion analysis financial condition results operationsexpensesgains board directors james cornelius laurie h glimcher md vicki l sato phd chairman chief executive officer irene heinz given professor professor management practice bristolmyers squibb immunology harvard harvard business school school public health professor molecular cell lamberto andreotti professor medicine harvard biology harvard university cd president chief operating officer medical school abd bristolmyers squibb togo west jr michael grobstein chairman tli leadership lewis b campbell retired vice chairman group noblis inc bc lead independent director ernst young ac bristolmyers squibb r sanders williams md chairman president chief leif johansson senior vice chancellor executive officer textron inc abc president ab volvo academic affairs chief executive officer duke university bd louis j freeh volvo group ac president freeh group international solutions llc managing partner alan j lacy audit committee freeh sullivan sporkin llp ab senior advisor oak hill b committee directors corporate governance capital partners lp ab c compensation management development committee science technology committee management council james cornelius brian daniels md anthony mcbride phd chairman senior vice president senior vice president chief executive officer global development medical human resources affairs research development lamberto andreotti elliott sigal md phd president carlo de notaristefani cirm executive vice president chief operating officer president technical operations chief scientific officer global support functions president batrice cazala research development president global commercialization anthony c hooper president europe president americas robert zito senior vice president john e celentano jeanmarc huet corporate business president emerging markets executive vice president communications asia pacific chief financial officer chief communications officer sandra leung senior vice president general counsel corporate secretary executive committee member stockholder information common stock product names company programs ticker symbol bmy new york free copy companys annual product names company programs stock exchange report fiscal year appearing throughout italics ended december contact trademarks bristolmyers squibb annual meeting stockholders secretary company one divisions tuesday may bristolmyers squibb company subsidiary companies global products referred herein registered bristolmyers squibb company park avenue approved us trademarks unless scudders mill road new york ny specifically noted otherwise plainsboro nj also available abilify trademark stockholder services programs wwwbmscominvestors otsuka pharmaceutical co ltd inquiries concerning stockholder accounts stock transfer matters recent certifications atripla trademark including address changes elim companys chief executive officer bristolmyers squibb ination duplicate mailings chief financial officer pursuant section gilead sciences llc investor services programshould sarbanesoxley act directed company 's transfer filed exhibits companys avapro avalide aprovel agent registrar company also filed karvea iscover plavix mellon investor services llc new york stock exchange trademarks sanofiaventis recent annual ceo certification washington boulevard bufferin excedrin japan required section aa jersey city nj asia excluding china taiwan new york stock exchange listed certain oceanic countries wwwmelloninvestorcomisd company manual trademarks lion corporation within us information following subjects dovonex trademark outside us available wwwbmscom leo pharma tdd telephone service bristolmyers squibb foundation hearingimpaired enfamil trademark within us sustainabilityenvironmental programs mead johnson company political contributions outside us erbitux trademark diversity eeo report eli lilly company investor services program investor services program designed annual report contains certain gleevec trademark longterm investors wish build forwardlooking information within novartis ag meaning private securities litigation share ownership company 's com similac trademark reform act forwardlook mon stock time participate abbott laboratories ing statements involve substantial risks program registered holder company 's common stock uncertainties could cause truvada trademark company 's com actual results differ materially gilead sciences inc expectations estimates reflected mon stock become participant forwardlooking statements please making initial purchase directly see financial review program program discussion description risks features dividend reinvestment optional uncertainties company cash purchase share safekeeping takes obligation publicly update share sales transfers bristolmyers forwardlooking statement whether squibb appointed mellon bank na result new information future administrator program events otherwise program sponsored administered bristolmyers squibb company bristolmyers squibb annual reporton right age sandra ragan jacksonville florida feeling tired usual doctor told type diabetes ive got diabetes family says still shocking get diagnosis doctor recommended diet exercise enrolled clinical trial dapagliflozin investigational compound discovered bristolmyers squibb scientists dapagliflozin developed collaboration astrazeneca treatment type diabetes chronic disease occurs body produce enough insulin use insulin produces world health organization estimates million people worldwide diabetes type dia betes also called noninsulindependent adultonset repre sents percent diabetes cases following doctors recommendations sandra feeling better also energy picked things need includes spending time four daughters nine grandchildren pictured right sandra two grandchildren danielle pacie back cover kevin sharp going let diagnosis cancer get way dream become country songwriter recording artist dream sustained two years treatment age kevin living dream platinum debut album string hits cancer remains remission kevin others prevailing serious diseases go wwwbmscom copyright bristolmyers squibb company rights reserved produced bristolmyers squibb communications departmenttogether prevail park avenue new york ny wwwbmscom